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ABSTRACT 
Objective: 
Several studies have highlighted the detrimental effects of alcohol dependence upon 
bone health, but the majority of data relate to male alcoholics. In general, these 
effects are considered to be either a direct toxic effect on bone or related to 
confounding lifestyle factors linked to alcohol dependence. Given the rising 
prevalence of alcohol dependence in young women, data relating to this group are 
timely. We performed a study to assess bone health in this population and 
specifically to study change in bone turnover following admission to an alcohol 
detoxification unit in New Zealand.  
Materials and methods: 
We studied 20 women admitted to the Kenepuru alcohol withdrawal unit. After 
obtaining written consent, women completed lifestyle questionnaire detailing 
demographic information, and questions relating to cigarette and alcohol 
consumption, physical activity, dietary calcium intake. Fall and fracture history was 
also elicited. Heel ultrasound was performed with a GE Achilles instrument, to obtain 
measures of Speed of Sound (SOS), Broadband Ultrasound Attenuation (BUA), 
Stiffness Index (SI) and T score bone mineral density (BMD). ). We supplemented 
our study with a similar data collection protocol in 16 healthy staff members without a 
diagnosis of alcohol dependence.  Fasting blood samples were obtained in a subset 
of 6 premenopausal alcoholic women and a marker of bone formation [serum 
procollagen type 1 N propeptide (P1NP)] and bone degradation [serum C-terminal 
cross-linking telopeptide of type 1 collagen (CTX)] measured. Matched samples 
were obtained fasting on the day of admission (day 1) and the day of discharge (day 
5). Ethical approval was given by the Central Health and Disability Ethics Committee. 
Among women with alcohol dependence, the mean age was 45.2 (SD 8.97) years. 
Risk factors for osteoporosis were common, and much higher in this group than in 
the control group of healthy volunteers of similar age.  Women had been drinking 
heavily for a mean of 16.3 years, and 75 % were current smokers. The mean 
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calcium intake in the group was very variable (range 121.41 mg to 2838.9mg daily). 
Five women (25%) reported moderate physical activity over the preceding 7 days; 15 
women (75%) reported falls in the preceding year. 
Table 1 shows the mean marker values on day 1 and day 5, available in a subset of 
6 premenopausal, Caucasian women. While significant differences were seen in 
P1NP over the admission period, change in CTX failed to attain statistical 
significance in this small sample. 
 Day 1 mean (SD) Day 5 mean (SD) P value difference 
P1NP (µg/l) 23.08 (9.52) 27.88 (8.04) 0.04 
CTX (µg/l) 0.14 (0.072) 0.14 (0.09) 0.85 
 
Discussion: 
In conclusion, lifestyle factors associated with poor bone health are prevalent in this 
population. Even within the limited sample size, significant differences were seen in 
change in BTM over a 5 day period following abstinence from alcohol in an alcohol 
dependent group; further work is now indicated in a larger sample size to assess 
speed and size of response.  
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Chapter One: Introduction 
1.0 Introduction: 
This thesis investigates the association between alcohol dependence and bone 
health in a group of New Zealand women admitted to an alcohol detoxification unit. 
While the intention of this study was to recruit 50 – 100 women, slow accrual rates 
necessitated the recruitment of a healthy control group without a history of alcohol 
dependence from staff at the Unit to provide a comparison group. We investigated 
relationships between alcohol intake and heel ultrasound measures; 
interrelationships between alcohol intake and other lifestyle factors detrimental to 
bone health; and change in bone turnover markers over a 5 day period following 
admission to the alcohol detoxification unit. 
  
1.1 Osteoporosis – an overview: 
Osteoporosis is defined by the World Health Organization (WHO) as a disease 
characterized by reduced bone mass and micro architectural deterioration of bone 
tissue [1]. This low bone mass makes the bone brittle and increases the risk of bone 
fracture [2]. 
 
Osteoporosis can be developed as a primary disorder or may be a result of other 
medical diseases such as gastrointestinal diseases, Rheumatoid Arthritis or 
endocrine diseases, surgical procedures or medications such as corticosteroids 
which lead to bone loss [3]. 
 
The main cause of postmenopausal osteoporosis is a drop in the circulating 
oestrogen level in women after the menopause, while in men a corresponding 
decrease in oestrogen and testosterone occurs. Women over the age of 50 and men 
over 70 years are hence more susceptible to osteoporosis [4]. Other identified risk 
factors for osteoporosis include: 
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1. Family history of Osteoporosis  
2.  Rheumatoid Arthritis, 
3.  Chronic Kidney disease  
4. Hyperparathyroidism 
5. Vitamin D deficiency 
6. Inadequate dietary calcium intake 
7. Consumption of high amounts of alcohol 
8. Smoking 
9. Amenorrhea, possible in association with eating disorders 
10. Low body mass index for other reasons 
11. Drugs used in breast cancer and prostate cancer therapy 
 
At the early stages, before fragility fracture occurs, many patients are asymptomatic 
and hence undiagnosed. However, with greater reduction in bone density and 
consequent fracture, the patient may remark on tenderness/ bone pain due to micro 
fracture or low back pain and neck pain due to vertebral fracture which may also 
result in kyphosis. [4] 
 
1.2 The Bone Remodelling process: 
 
There are multiple reasons why the bone may become fragile. These include :a 
failure to produce sufficient bone mass and strength (peak bone mass), excessive 
bone resorption which reduces bone mass and results in micro-architectural 
deterioration of the skeleton, often coupled to an inadequate formation response to 
increased resorption during bone remodelling[5] 
 
Bone remodelling is the process which helps in formation of new bone in the human 
body by preforming the resorption of old bone [5]. Osteoclasts and osteoblasts are 
the main cells which in addition with other accessory cell types perform bone 
remodelling [5].  
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Below is a schematic representation of the phases which take part in bone 
remodelling: 
 
 
Figure 1:  Bone remodelling schematic representation 
The first step in bone remodelling is activation of osteoclasts [5].  During activation, 
the mononuclear osteoclasts precursors meet on the bone surface and fuse to form 
osteoclasts [5]. Receptor activator of nuclear factor-kB ligand (RANKL), IL-1, IL-6 
(InterLeukins), systemic hormones like PTH, 1,25-dihydroxyvitamin D3 and calcitonin 
are the local cytokines which help in formation, activation and activity of 
osteoclasts[5]. RANK, which is the cognate receptor of RANKL is the main regulator 
of the osteoclast [5].  
 
The reversal phase is the next step after the resorption phase. Apoptosis causes the 
death of osteoclasts and mononucleated resorbing cells [5]. Osteoblasts are the cells 
which then replace the osteoclast and proceeds the cycle in formation phase [5]. 
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Osteoblasts traverse the bone surface via cortex where they refill the cortex by 
depositing it within osteon; a lamellar bone [5].  
 
Throughout the formation phase in the matrix, the osteoblasts are buried and formed 
into osteocytes [5].  Osteocytes maintain contact with one another as well as with the 
cells on the surface of the bone; this helps in sending signals to the cells on the 
surface to regulate the bone remodelling process whenever necessary [5].  
 
The resorption and reversal phase of the bone remodelling process are short while 
the formation process is long. In instances where there is any increase in the rate of 
the remodelling of bone, the bone mass will be reduced [5].  The important factor in 
osteoporosis is thus the inadequate formation response during bone remodelling [5]. 
 
 
1.3 The role of oestrogen in bone remodelling: 
 
As mentioned previously one of the major factors in the pathogenesis of 
osteoporosis in postmenopausal women is oestrogen. Research studies show that 
oestrogen plays a significant role in bone loss in older women [5]. Although 
oestrogen is important for bone turnover in both the sexes, it has been seen that with 
a decrease in oestrogen, the rate of bone remodelling increases and amount of bone 
lost per remodelling cycle is also increased with oestrogen deficiency in the body [5].  
 
Oestrogen acts on the body via its 2 receptors ERα and ERβ. Studies show that 
there is also an orphan nuclear receptor: oestrogen receptor-related receptor α 
(ERRα) which is also present in bone cells along with receptors ERα and ERβ [5]. 
This receptor may interact with receptors ERα and ERβ or may directly modify the 
bone cell function [5].  
 
The schematic representation of oestrogen action shown overleaf in Figure 2 [40] 
helps to explain the process: 
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Figure 2: Mechanism of action of oestrogen 
 
 
Figure 3: process of bone remodelling on trabecular bone 
 
Figure 3 shown above shows the process of bone remodelling on trabecular bone. 
The osteoclasts are activated when hematopoietic precursors interact with cells in 
osteoblastic lineage. After the formation of osteoclasts, the resorption phase starts 
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which is then followed by the reversal phase. In the reversal phase, the mononuclear 
cells cover the bone surface. The next phase involves the formation phase. In this 
last phase of the bone remodelling process, the matrix is developed with the help of 
osteoblastic waves. These are then formed into osteocytes which then embed in the 
bone or die due to apoptosis.   
Specifically, the action of estrogen shows an effect on: 
i. T cell cytokine production. 
ii. Effect on osteoblasts to alter their production of RANKL or OPG 
(osteoprogesterin). 
iii. Direct inhibition of osteoclasts. 
iv. Effect on formation of bone by osteoblasts. 
 
In osteoporosis, the rate of bone resorption exceeds the rate of bone formation. With 
a decrease in oestrogen level, cytokines level increases which lead to increase in 
bone resorption [6].   
  
1.4 Causative factors for osteoporosis: 
 
As mentioned previously there are many factors which may lead to osteoporosis and 
the risk increases with the number of possible factors present. 
 
1. Genetic factors: 
 
Family history of hip fracture or any other osteoporotic fracture increases the risk of 
fracture in the individual.  
 
2. Hormones: 
 
The role of oestrogen has been discussed in detail above. 
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3. Age: 
 
It has been observed that as age increases, bone mineral density (BMD) decreases 
increasing the chances of osteoporotic fragility fracture [6].This is demonstrated 
graphically in figure 4 [6].  
 
 
 
 
Figure 4: Changes of bone mass with Age 
 
In both males and females, bone mass reaches its peak in early adult life with a 
gradual decrease thereafter [7]. In women, after the menopause concludes, a more 
gradual decrease in bone mass has been observed. The fracture threshold here 
shows that with a decrease in bone mass, the risk of fracture increases [7]. 
 
4. Previous history of fractures: 
 
Several studies have shown that individuals with a prior fragility fracture have a 
greater risk of suffering a further fracture [6, 7]. 
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5. Smoking: 
 
A meta-analysis of the relationships between smoking and BMD has shown that 
BMD in smokers is decreased by up to 2% [6, 7]. Furthermore, the risk of being 
osteoporotic is greater in current smokers as compared to previous smokers. [7] 
 
6. Excessive alcohol consumption: 
 
Excessive alcohol consumption is also one of factors that may increase the chance 
of osteoporosis and will be discussed in greater detail later. 
 
7. Vitamin D and calcium: 
Vitamin D plays an important role in the absorption of calcium and bone health. 
Figure 4 shows how vitamin D is manufactured and taken into the body, and how its 
metabolism interacts with calcium absorption to ensure bone health. The role of this 
hormone and the consequences of deficiency are described in more detail later in 
this chapter. 
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Figure 5: Schematic representation of cutaneous production of vitamin D  
 
When the skin is exposed to sunlight, 7-dehydrocholesterol (7-DHC) which is present 
in the skin absorbs the UV rays and is converted to previtamin D3 (PreD3).  This  
previtamin D3 goes through a thermally induced transformation and converts into 
vitamin D3. Vitamin D which is produced from diet or skin enters into the circulation 
and gets metabolised by vitamin D 25-hydroxylase (25-OHase) to 25 (OH)D3  in the 
liver. In the kidney, 25 (OH)D3   gets converted to 1, 25(OH)2D3 with the help of the 
enzyme 25 (OH) D3 1α- hydroxylase (1-OHase). Factors such as Pi  ( serum 
phosphorous) and PTH help in regulating the production of 1, 25(OH)2D, which helps 
in calcium metabolism through interacting with bones and the intestines. 1, 
25(OH)2D, gets converted to 25 (OH)D 24-hydroxylase (24-OHase).  25(OH)D is 
metabolised in other tissues for cell growth regulation. 
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8. Exercise: 
 
Numerous studies have shown that physical activity protects against osteoporosis. 
Individuals with a sedentary lifestyle are at higher risk for osteoporosis as compared 
to those who exercise daily [6, 7]. Performing weight bearing exercise has been 
shown to increase bone density. 
 
9. Secondary Osteoporosis: 
 
In addition to the above risk factors, there are some secondary causes which may 
cause osteoporosis. 
 
1. Clinical disorders such as anorexia, chronic liver disease, coeliac disease, 
hyperparathyroidism, irritable bowel syndrome, male hypogonadism, renal 
disease, rheumatoid arthritis may also lead to secondary osteoporosis [7]. 
 
2. Corticosteroids: 
Use of long term corticosteroids increases the risk of non-vertebral fracture 
within 3 months of treatment initiation. Studies prove that even with a low 
dose of glucocorticosteroids, the chances of secondary osteoporosis increase 
[7]. 
 
 
1.5 The classification of osteoporosis: 
 
Using the WHO definition, osteoporosis is based on the T score derived from the 
measurement of Bone Mineral Density. T score is measured as the number of 
standard deviations below the average for a young adult at peak bone density when 
compared to a reference population [7]. 
 
WHO has defined the below mentioned categories on the basis of bone mineral 
density in women: 
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a. T-score better than -1 : Normal  
b. T-score between -1 and -2.5 : Osteopenia 
c. T-score less than -2.5 : Osteoporosis 
d. T-score less than -2.5 with fragility fracture :  established osteoporosis 
 
In addition to the T-Score, a Z-score is derived; A Z-score can be defined as the 
number of standard deviations from which a person’s   BMD differs from the mean 
BMD for the same age group of people [6,7]. Hence while the T-score is used as a 
score which can help in determining whether the patient is classed as suffering from 
osteoporosis, in young populations, it is less predictive for determining osteoporotic 
fracture risk [7]. For each one standard deviation decrease in BMD, the risk of 
fracture approximately doubles [7]. 
 
 
FRAX: 
Studies have shown that T-Score alone cannot predict the risk of fracture, Hence the 
WHO has developed a model called the FRAX tool.  This tool was developed to 
calculate the 10-year risk of osteoporotic fractures of an individual and is calculated 
using information on clinical risk factors and BMD [7]. The clinical risk factors that are 
included in the FRAX algorithm are: Age, Sex, Weight (kg), height (cm), prior fracture 
status, family history of hip fracture, Rheumatoid arthritis,  3 or more units of alcohol 
consumption daily, and other causes of secondary osteoporosis. 
 
The FRAX tool calculator screen is shown below. 
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Figure 6: FRAX tool 
 
The National Osteoporosis Foundation (NOF in U.S.) and National Osteoporosis 
Society (NOS in U.K) have added the FRAX tool to BMD scores in their guidelines 
for identifying the individuals with high fracture risk [7].  
 
Despite the above mentioned advantages of the FRAX algorithm, there are certain 
limitation that has been observed. Firstly the FRAX algorithm does not take into 
account the ‘dose effect’ of risk factors like glucocorticoids. Furthermore, no data is 
collected about prior fractures. 
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1.6 Bone quality: 
 
The strength of the bone is determined by its BMD, geometry and the quality of the 
bone [8]. The quality of the bone depends on many components including bone 
turnover, microarchitecture and composition of the bone matrix [8]. All these 
components are mutually dependent on each other and thus if any of the component 
has some abnormality, the effect is observed on all the others.  
 
Of all the components of bone quality, bone turnover plays a pivotal role in 
determining these. Section 1.2 summarises the bone remodelling process. 
 
The most common method of assessing bone turnover is by measurement of 
biochemical markers of resorption and formation [8].  These markers show 
inconsistency both within and between individuals and are dependent on diet. 
Therefore, samples should be collected with the patient in a fasting stage [8]. 
Another less often used method to assess the bone turnover is by performing 
histomorphometric assessment of bone, with the help of tetracycline labelling prior to 
biopsy [8].  
 
 Bone microarchitecture also contributes to bone quality. Any changes in 
microarchitecture have a direct effect on the strength of the bone thereby damaging 
bone quality [8].  These architectural features can be assessed using high resolution 
magnetic resonance imaging (HR-MRI), high resolution peripheral quantitative 
computed tomography (HR-pQCT) and micro-CT (µCT). 
  
Finally bone quality is also affected by bone mineralisation. Mineralisation of the 
bone occurs in 2 phases: deposition of bone mineral in the bone remodelling process 
is called primary mineralisation. Secondary mineralisation is defined as the process 
of mineralisation after the completion of the bone remodelling process [8]. The 
degree of bone mineralisation is measured by bone mineral density measurements, 
but is not the main factor in determining the BMD [8]. 
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1.7 Bone Turnover: 
 
As has been discussed, in section 1.2 bone turnover consists of 2 activities namely 
formation of bone and resorption of bone.  The rate of formation of bone is calculated 
by measuring the enzymatic activity of bone forming cells [8]. Based on their origin, 
bone turnover markers are divided into formation and resorption markers. In disease 
like osteoporosis where both formation and resorption process are coupled together 
and may change in the same direction, these markers will reproduce the overall rate 
of bone turnover [8].   Bone turnover markers are the biochemical products present 
in blood or urine. They have the capability to reflect metabolic activities of bone and 
are said to be markers for bone formation and bone resorption [9].  During the 
activation of osteoblasts, direct and indirect products are released which are said to 
be bone formation markers [9]. During bone formation process, precursor 
procollagen of type I    collagen is secreted [9]. At both the ends of procollagen 
molecule there are extension peptides namely, procollagen type I N propeptide 
(PINP) and procollagen  type I C propeptide (PICP) [9].  These extension peptides 
are released into circulation during the process of bone formation are called as bone 
formation markers [9]. During bone formation, osteoblasts produce osteocalcin [9].  
The kidneys play a pivotal role in extraction of Osteocalcin and it can found in urine 
[9]. 
 Another bone formation marker is ALP (alkaline phosphatase). ALP can be 
measured in serum as it is secreted in blood by osteoblasts [9].  As ALP, is mostly in 
hepatic origin, assays help in identifying bone derived isoform of ALP called as BALP 
[9].  
 
The most common bone resorption markers used are tartarate resistant acid 
phosphatase 5b (TRACP).  During bone resorption, pyridinium crosslinks, pridinoline 
(PYD) and deoxypyridinoline (DPD) are released and excreted in urine in peptide 
forms. The peptide form of PYD and DPD are  C and N terminal crosslinking  
telopeptides (CTX and NTX) of type I collagen molecule [9].  
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1.7.1 Bone formation markers: 
 
1. Procollagen I extension peptides: 
Osteoblasts produce the type I collagen as procollagen with extension peptides in 
carboxy (C) and amino (N) ends [10]. 
 
2. Bone specific alkaline phosphatase: 
Bone specific alkaline phosphatases (BSAP) are produced by osteoblasts at the time 
of matrix production. 
 
3. Osteocalcin: 
Osteocalcin is a non-collagen protein located in bone. Osteocalcin plays an 
important role in mineralisation of bone.  
 
1.7.2 Bone resorption markers: 
 
1. Telopeptides of type I collagen: 
Degradation of non-helical region of type I collagen in amino-terminal region (NTX) 
and carboxy-terminal region(CTX) produces these peptides [10]. NTX and CTX can 
be measured in serum or urine. 
 
2. Pyridinium cross-links: 
After the catabolization of collagen, the cross links are released in the circulation 
[10]. These cross link are available in serum or urine in 2 types namely pyridinoline 
and deoxypyridinoline [10]. 
 
3. Acid phosphatase: 
Acid phosphatase is an iso-enzyme which is produced by osteoclasts [10].  
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1.8 Use of bone turnover markers 
 
With an increase or decrease in these bone turnover markers, it may be possible to 
predict risk of osteoporotic fracture [10]. Research shows that age and sex are 
important factors in influencing the level of bone turnover markers.  It has been 
observed that in children and postmenopausal women, bone turnover markers are 
generally higher than is usually observed in an adult group [10].  Many cohort studies 
have been conducted with some suggesting that in general the higher levels of 
resorption markers the higher the risk of non-vertebral and vertebral fractures [10].  
 
However, the main use of bone turnover markers is now in monitoring the response 
to drug therapy [10]. There are many factors that govern the changes in bone 
turnover markers including: route of drug administration, marker type and cellular 
mechanism of the drug’s action [10]. For example bisphosphonates administered 
orally decrease bone resorption markers in 3 weeks. Bone resorption markers 
decrease as the dose of bisphosphonates increases [10]. 
 
During the menopause, estrogen levels decrease, which leads to increased bone 
turnover and disturbance in the balance between bone formation and bone 
resorption.  In postmenopausal women, bone turnover is normally high with high rate 
of bone loss, thereby leading to bone fragility and increased risk of fracture [11]. 
 
A study was conducted to assess the capability of biomarkers bone specific alkaline 
phosphatase (BALP) and creatinine corrected urinary C-telopeptide (CTX) to predict 
osteoporotic fracture risk in post- menopausal women [11].  721 women participated 
in the trial and during 1992-1994 serum samples were collected from 512 women 
[11]. With the help of single energy X-Ray densitometry, bone density was measured 
[11]. At baseline, urine samples were also collected along with serum samples [11]. 
With the help of immunoradiometric assay, serum BALP was measured, while 
urinary C-telopeptide was measured with an enzyme linked immunosorbent assay 
[11].  To reduce urinary volume effects the results for this biomarkers were 
measured as a ratio of  C-telopeptide to urinary creatinine (urinary CTX) [11].  In 33 
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women new vertebral fractures were identified, while in 25 women new non spine 
fractures were diagnosed [11]. Also, 10.7% of the women had suffered from at least 
1 fracture since first visit [11].  Baseline BALP and CTX levels were increased in 
women with osteoporotic fractures as compared to women with no fracture recorded 
[11].  The odds ratio for calcaneus BMD (for spine fractures was 1.49), BALP (for 
spine fractures was 1.49) and CTX (for spine fracture was 1.33) showed that they 
play a significant role in predicting the fractures in these women [11].    
The study results suggest that in postmenopausal women, bone turnover markers 
play a significant role in predicting fractures [11].  
 
A further study assessed the ability of 7 bone turnover markers to predict risk of 
fractures in 1040 elderly women [12]. The study follow up period was 9 years [12]. All 
women included in the trial were aged 75 years and above [12].  Serum and urine 
samples were collected at baseline and follow up was at 1 year [12].  A real BMD 
was obtained for 931 women at total body, 926 at total hip, and 974 at lumbar spine 
[12].  The 7 bone turnover markers that were assessed included: a) Bone resorption 
markers: tartarate resistant acid phosphatase 5b (TRAP) and serum C-terminal 
cross linked telopeptide (S-CTX-I) and b) Bone formation markers: serum bone 
specific alkaline phosphatase (BALP), and 3 assays for different molecular forms of 
osteocalcin [12]. The 3 forms of osteocalcin assessed were: Serum intact 
osteocalcin (S-OC[1–49]), serum total osteocalcin (S-TotalOC), and serum g-
carboxylated osteocalcin (S-cOC) [12].  With addition to serum, osteocalcin assays 
were also performed for urine osteocalcin (U-OC) [12].  The fracture history of the 
patients who participated was obtained and for the follow up in predicting fractures, 
date of first fracture was considered as an endpoint [12]. The results of this study 
showed that during the 9 year follow up, of 1040 women, 363 women sustained at 
least 1 fracture [12].  In total 116 women had a hip fracture and 103 were reported to 
have vertebral fractures [12]. It was also observed that women who reported a 
fracture at baseline had low BMI and low weight when compared with women who 
did not report any fracture at baseline [12]. They were also reported to have a lower 
BMD [12].  The results also suggested that baseline bone resorption markers helped 
in identifying the fracture risk as the hazard ratio for S-TRACP5b was 1.16 and for S-
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CTX-1 was 1.13 [12].  These markers also predicted an increased risk of vertebral 
fractures with HR 1.22 for S-TRACP5b and 1.32 for S-CTX-I [12]. However, bone 
formation markers S-OC, S-Total OC, S-c0C and S-BALP were not able to predict 
fracture risk [12]. The study also found that none of the 7 bone turnover markers 
were able to predict the risk of fracture for hip [12].  
 
Hence while some studies suggest that bone turnover markers can help in predicting 
risk of fracture, there are some limitations which were observed in the use of bone 
turnover markers. It is recognised that several factors influence bone turnover 
markers, including menopausal status, sex, age, gender, food intake. [13]. For 
example, menopausal status and female sex increases  bone turnover markers level, 
while food intake affect serum –CTX-1 level (bone resorption markers) but does not 
have any effect on bone formation markers [13]. 
 
1.9 Public health importance of osteoporosis: 
 
Osteoporosis is a disease that causes premature mortality and morbidity [14]. 
Studies show that 1.5 million annual fractures including hip fractures are attributable 
to osteoporosis [14]. 
Research shows that in United States, more than 10 Million people above 50 years 
of age suffer from osteoporosis and fragility fractures, while in United Kingdom, one 
in every 8 women over 50 years of age have osteoporosis fractures [14].  1.67 
million hip fractures had been reported globally in 1990, leading to 740000 deaths 
due to fractures per year [14]. Hip fractures are said to be the main reason for 
healthcare burden because of the need for immediate hospitalisation and long term 
care [14].  
By contrast vertebral fractures are often asymptomatic. In the US, the estimated 
lifetime risk of clinically-diagnosed vertebral fracture is 16% in white women and 5% 
in white men.  In Great Britain, the rates are slightly lower at 11% in white women 
and 2% in white men [14]. 
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Hence public health initiatives aim to educate and spread awareness in women and 
their clinicians about osteoporosis, in an attempt to reduce fracture incidence and 
associated morbidity and mortality. [14]. Lifestyle measures that will protect against 
osteoporosis and are often promoted in public health initiatives include maintaining 
an adequate calcium and vitamin D intake, maintain weight bearing physical activity, 
avoiding cigarette smoking and keeping alcohol intake to within recommended levels 
(14 units per week in women)[14]. 
 
 
1.10 Perception of Osteoporosis risk: 
 
Several studies have been conducted on osteoporosis education. After the 
completion of such programs, improvement in terms of knowledge about 
osteoporosis, and what steps to be taken to prevent osteoporosis have been 
assessed in those women [15]. In one study, an osteoporosis prevention program 
(OPP) focused on non-compliance concerning recommendations which were 
provided to prevent osteoporosis [15]. One of the observation noted while this 
program was taken was a belief that osteoporosis is not serious [15]. This program 
consisted of 3 sections: education classes, bone mineral density testing and 
individual consultation [15].  
 
Participants were told about the importance of physical activity and exercise in 
osteoporosis. Benefits of weight bearing exercise were shared with the participants 
[15].  Bone mineral density testing was performed for all participants using dual 
energy X-ray absorptiometry (DEXA) [15] and results fed back. The participants were 
educated regarding diet intake, which exercises should be done and how to take 
care if you are suffering from osteoporosis [15].   
 
The Global Longitudinal Study of Osteoporosis in Women (GLOW) also focused in 
part on women’s perception of fracture risk [16]. This study was performed in 10 
countries and 60393 women over 55 years of age participated [16].  
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 This study highlighted several risk factors for fracture including  age, low weight, 
family history of hip fracture, personal history of fracture, 2 or more falls in last one 
year, use of corticosteroids and consumption of alcohol daily [16].   This study, like 
the others, highlights the knowledge and perception gap among women at risk of 
osteoporosis. 
 
Several other studies have been conducted on promoting the health and awareness 
about osteoporosis. The inclusion criteria for the trial were postmenopausal women 
with over 50 years of age [17].  Calcium intake was measured based on dietary 
intake [17]. A note was taken of the exercise levels among participants. [17]. Another 
study was based on Pender’s Health Promotion Model (HPM) [18]. HPM had three 
components: cognitive factors, modifying factors and cue of action [18]. The 
cognitive factors consist of perception of benefits and barriers to behaviour, self-
efficacy, health control and importance [18].  Demographic, biologic, interpersonal 
and behavioural factors come under modifying variables [18]. Transient stimuli to 
behaviours are the cue of action [18]. The study concluded that awareness of 
osteoporosis should be heightened among young women.  
 
 
1.11 Impact of osteoporosis on quality of life 
 
 Health related quality of life (HR-QoL)is affected in women suffering from 
osteoporosis.  An instrument has been developed called the osteoporosis-targeted 
quality of life survey [19]. This survey focuses on three sections: physical difficulty, 
adaptation to daily life and fears about the future [19]. This method helped in 
identifying the difference between those with normal bone mineral density, 
osteopenia and osteoporosis [19]. 
 
A cross sectional survey was performed to check the impact of HR-QoL on 
premenopausal and postmenopausal women suffering from osteoporosis [19].  The 
survey consisted of questions based on 3 sections along with health related 
questions such as prior fractures etc [19].  The results showed that the chance of 
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suffering from osteoporosis, and consequent adverse effects such as, postural 
changes, were observed mainly in older women. Women over the age of 65 years 
had a mean domain score of 17.9 to 34.1 as compared with a mean domain score of 
7.4 to 9 in women below 65 years of age [19,20].  The adaptation and fear score 
were worse in women whose T-scores were in the range of osteoporosis [19, 20].    
The study results suggest that fractures and fear of fracture have a great impact on 
quality of life.   Fear was another factor which had an impact on QOL [19, 20].  The 
QoL score was compared with BMD and was observed that those with low BMD had 
worst QoL score [20].  
 
1.12 Prevalence of vitamin D insufficiency in New Zealand: 
 
Lack of vitamin D is associated with osteomalacia and osteoporosis and 
considerable research is being carried out on this topic globally. A high rate of 
vitamin D insufficiency is often reported in women with osteoporosis, although this is 
often also the case in healthy women as well [21].  
 
A diagram showing vitamin D metabolism is shown in section (figure 5) earlier in this 
chapter in the section 1.4 ‘Causative factors for osteoporosis’. Vitamin D is available 
in 2 forms namely ergocalciferol (vitamin D2) and cholecalciferol (vitamin D3) [22]. 
Vitamin D is transported to the liver via the circulation where it is converted to 25-
hydroxycholecalciferol (25OHD) by the enzyme 25-hydroxylase [22]. This is further 
converted to 1,25-dihyroxycholecalciferol in the kidney [22].  125-
dihydroxycholecalciferol is pivotal in promotion of bone mineralisation and calcium 
absorption [22].  
 
The most abundant source of vitamin D is usually UV rays in sunlight.  Research 
shows that vitamin D play an important part in enhancing the activity of osteoclasts 
and stimulates bone formation and maturation [22]. It has also been suggested that 
vitamin D and parathyroid hormone (PTH) help in the metabolism of Ca and P [22].   
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Many studies have shown that vitamin D deficiency causes bone loss in women and 
low BMD when compared with women with no vitamin D deficiency [22]. 
 
The groups of people in which the chance of low vitamin D is highest are, according 
to a recent study [22]: 
a. Patients with hip fracture 
b. Mothers of infants having rickets. 
c. Older people admitted to hospital 
d. People with no exposure to sun for a long period of time [22].  
 
Research on vitamin D levels has been conducted in Australia and New Zealand 
populations [22].  Researchers characterized vitamin D deficiency into 3 categories: 
Mild vitamin D deficiency, when range of the serum 25-OHD is 25-50nmol/L, leading 
to increased bone turnover and high level of PTH secretion [22]. 
Moderate vitamin D deficiency, when the range of serum 25-OHD  is 12.5-25 nmol/L 
[22]. Bone turnover is increased in this group, who may also have low BMD and an 
increased risk of hip fracture in older people [22]. Finally 
Severe vitamin D deficiency, in which category levels of serum 25-OHD are less than 
25 nmol/L and patients suffer from osteomalacia [22]. The study results concluded 
that while there were rare chances of severe vitamin D deficiency in Australia and 
New Zealand, most cases were mild deficiency [22].  
 
In another study conducted in the NZ population on individuals of age 15 years and 
older to determine the serum level of 25-hydroxy vitamin D [23], researchers found 
that the mean serum 25-hydroxyvitamin D concentrations were 47 (45–50) nmol/l in 
women and 52 (49–55) nmol/l in men. 3% of the New Zealanders were identified 
with deficiency in serum 25-hydroxy vitamin D levels [23].  It has been suggested 
that people in NZ may be at risk of low serum levels of vitamin D for the following 
reasons: high latitude in the country with over 35– 47° S; high use of sunscreen;  
lifestyle which leads to less outdoor activity [23].   
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Research also shows that ethnicity plays a role in vitamin D levels and as the New 
Zealand population has 3 main different populations viz. Maori, Pacific and 
Europeans (among others) the level of vitamin D in all the 3 categories vary [23]. As 
the Maori and Pacific Origin populations have a comparatively darker skin compared 
to their European origin counterparts, they tend to have low levels of serum vitamin 
D. Furthermore, food intake also plays a significant role in vitamin D levels in the 
body. In New Zealand, it had been observed that fatty fish and organ meats are not 
consumed on a regular basis, which may be another factor contributing to low 
vitamin D levels [23].   
 
The National Nutrition survey was conducted in 1996-1997 in NZ on adults aged 15 
years and older [23]. 3946 participants were included in this study whose results 
showed that the lowest serum 25-hydroxy vitamin D was observed in pacific women 
with a mean concentration of 34 nmol/L (29-40) [23], while  European men had the 
highest mean serum 25-hydroxyvitamin D concentration (53 nmol/L) [23].  Half of the 
participants were classified as deficient in vitamin D as serum 25-hydroxyvitamin D 
concentrations were less than 50 nmol/L and more than 80% of the population had 
serum concentration less than 80 nmol/L  [23]. Women had lower levels of vitamin D 
serum concentration than men by 5 nmol/L [23].  It was also noted that the mean 
serum concentration of 25 (OH) vitamin D in Maori women was 11 nmol/L and in 
Pacific women was 16 nmol/L lower when compared to European women [24], while 
the mean serum 25 (OH) vitamin level in Maori men was 10 nmol/L lower and in 
Pacific men was 12 nmol/L as compared with European men [24].  
 
 
 1.13 Techniques to assess bone mass: 
 
Heel Ultrasound: 
 
The most widely used methods to measure BMD are dual energy X-ray 
absorptiometry (DEXA), heel ultrasound (HUS) and quantitative computerised 
tomography (QCT) [25]. 
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Quantitative heel ultrasound is a technique which was first launched in 1984 [25]. 
QUS uses sound waves [25]; the physical and mechanical properties of bone modify 
the speed, shape and intensity of the wave [26]. While QUS cannot be used as a 
diagnosis for osteoporosis, heel ultrasound has been shown to be able to predict hip 
and all osteoporotic fractures in elderly women [26]. A meta-analysis of QUS of the 
heel and its ability to predict fractures was performed [26]. The eligibility criteria for a 
trial to be a part of this meta-analysis study were: prospective studies with baseline 
measurements in units done with a QUS method; fractures to be the main outcome 
and relative risk estimate should be provided for the fractures. The studies which 
were included had used QUS from 4 different manufacturing companies and had 
different parameters recorded. For example, studies using the Walker Sonix UBA 
device has reported broadband ultrasound attenuation (BUA); studies which used 
the McCue CUBA device have recorded BUA and speed of sound (SOS); studies 
that used the GE-Lunar Achilles device have recorded BUA, SOS and Stiffness 
Index (SI) and studies which had ultrasound device of Hologic Sahara had recorded 
BUA, SOS and the quantitative ultrasound index (QUI) [26].  Results showed 
variance among studies between the BUA and SOS measure and associated risk of 
fractures [26]. 
 
According to this meta-analysis, the 2 studies which used GE Achilles and Sahara 
devices in the same age group of the elderly population showed significant 
relationships between measured parameters and risk of fractures [26]. From this 
meta-analysis it can be concluded that  quantitative heel ultrasound can predict 
fractures [26]. 
 
In one such sample study conducted on women aged between 45 to 75 years in 
Bournemouth, U.K,  women aged between 45 to 75 and registered with 2 general 
practices in area of Bournemouth, UK , were asked to participate [27].  Measurement 
of the heel of the dominant foot was taken with a Achilles ultrasound densitometer 
[27]. The results of the ultrasound were obtained as BUA, SOS and SI parameters 
[27]. 4018 women in total were scanned for the study [27].  An inverse relationship 
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was observed between age and QUS results [27]. The RR of fracture with a one unit 
change in BUA was 1.4 (1.26-1.56). 
 
In another study conducted in more than 7000 women of >= 70 years of age [28] the 
(Swiss Evaluation of Methods of Measurement of Osteoporotic Fracture Risk) study,  
3 different ultrasound devices (2 of heel and 1 of phalanges) were assessed in 
detecting  the risk of hip fracture in women aged 70 years or more [28]. The trial was 
conducted between 1997-1999 and 7609 women participated. QUS devices that 
were used in this study were the Achilles+, Sahara and DBM Sonic 1200 (for 
phalanges) instruments [28]. Eligible women were aged more than 70 years and able 
to walk and perform daily activities, while exclusion criteria were a history of hip 
fracture or bilateral hip replacement [28]. Every 6 months follow up was performed 
and participants were asked questions about any changes, illness, or medications or 
fractures with the exact locations [28]. It was observed during follow up that 425 
women had started treatment for osteoporosis [28].   
 
All the 3 QUS devices measured different parameters: 
 Achilles+: This device is water based. It measures BUA in dB/ MHz, SOS in 
m/s and SI with a formula as SI= (0.67 x BUA) + (0.28 x SOS ) – 420. 
 Sahara: This is a dry system which uses an oil based gel [20]. This device 
also measures BUA and SOS along with QUI. QUI can be calculated as QUI 
= 0.41 x (BUA + SOS) – 571. 
 DBM Sonic 1200: This calculates the propagation of the US pulse through the 
first phalanges of last 4 fingers of the hand [20].  The parameter that the 
device measure is Amplitude Dependent speed of sound (AD-SOS) in m/s 
[28]. 
  
In this study, the participants were followed for almost 3 years and of 7609 recruits, 
data were available for 7062 women. [28]. Eighty women suffered a low-trauma hip 
fracture during follow-up.  For Achilles+ Machine, the mean T score calculated was -
1.7± 0.9 SD. For the Sahara, the mean T score was –1.4 ± 1.1 SD [28] while for the 
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DBM Sonic 1200, the mean T-Score was −3.1 ± 1.3 SD for AD-SOS [28]. Hence the 
mean score of the other 2 heel ultrasound devices were higher than the mean score 
for the DBM Sonic 1200 machine [28]. This difference may be because of variation in 
the reference population of the devices used.  It was also noticed that the majority of 
participants who sustained a hip fracture had low heel QUS when compared with 
subjects having no risk of fractures [28].   When these results were compared with 
another study (French EPIDOS Study), results were comparable.  In the EPIDOS 
study, 5662 women were included and participated for 2 years [28]. In this study, the 
HR of fracture per decrease of 1 SD, was 2.0 for Achilles+ BUA and 1.7 for SOS 
[28].  
 
Another study was conducted in 12958 elderly women [29]. The aim of EPISEM 
prospective cohort study was to assess the 10 year probability of osteoporotic hip 
fracture as assessed by combining heel bone ultrasound scores and clinical risk 
factors [29]. The EPISEM study was performed by combining databases of the 
EPIDOS and SEMOF studies [29]. 12958 women aged between 70 to 100 years 
participated in the trial.  The Stiffness Index (SI) parameter was used for analysis 
[29]. Along with this, 22 clinical risk factors combined from both the EPIDOS and 
SEMOF studies were used in this study, in which during the follow up period 307 hip 
fractures were reported [29]. In a multivariate study model, 6 out 22 clinical risk 
factors statistically significantly   predicted fracture risk. These were: BMI, history of 
fracture after 50 years of age, chair test results, history of fall for past 12 months, 
current cigarette smoking and diabetes mellitus]. The study showed that for 
predicting hip fracture for all ages, a model with SI alone, had a higher gradient of 
risk (GR) as compared with model using clinical risk factors alone (CRF) [29].   For 
example, in women aged 70 yrs; the gradient of risk for SI was 2.16 as compared to 
1.87 of CRF alone but when SI and CRFs were combined together an increase in 
GR was observed. For hip fractures, the average GR observed was 1.77 for SI and 
1.52 for CRFs respectively. [29]. But when both of them were combined, the GR 
observed was 2.10 [29].  Using these combined results, the study calculated the 10 
yr probability of hip fractures.  
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For example the 10 year probability of fracture for an 80 yr old women  varied from 
16.9% at a SI score of +2 to 52..6% at SI score of -3 [29]. When this was combined 
with 2 CRFs for these women, the score increased from 16.9 to 26.6% and from 
52.6% to 70.5% respectively [29].  
 
From all the above the role of QUS might be summarised as: 
 
a. QUS is an inexpensive (as compared with DEXA) method to predict risk of hip 
fracture. [29]. 
b. QUS is easy to perform, quick and safe as it does not use X-rays [29]. 
c. QUS can be used as an initial screening method for osteoporosis, but it 
cannot be yet considered as a test to diagnose osteoporosis [29]. 
 
1.14 Alcohol and its effect on bone: 
 
1.14.1 Overview: 
It is well- known that alcohol consumption worldwide has increased significantly in 
recent years. It is thought that consuming low amounts of alcohol can increase bone 
density and bone mass while consumption of high amounts of alcohol has 
deleterious effect on bone [30]. There are many more studies conducted on men 
than on women with regard to the relationship between consumption of alcohol and 
its effect on bone [31]. This research project focuses on women who are alcoholics 
and admitted to an alcohol dependence unit to determine the effect of heavy alcohol 
consumption on bone as assessed by QUS; to look at the prevalence of other 
lifestyle factors associated with low bone density in this group and to relate the 
findings obtained to a control group of local women without a history of alcohol 
dependence. 
 
One of the few studies of female alcoholics to be conducted to determine bone 
mineral density and risk of fractures was conducted on 834 Caucasian women [31]. 
The required age for participation in the trial was 18 to 70 years [31].  
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These 834 women were divided in 3 groups: 228 women who were undergoing 
treatment for alcohol dependence, 156 women with a history of alcohol dependence 
and currently recovering, and 447 women in a group of non-alcoholic women [31]. 
BMD was measured for all participants and detailed questions were asked to 
determine the history of fractures, demographic information and history of smoking, 
reproduction and medical history [31].  Results of the study showed that women from 
the group who were currently undergoing treatment reported 10.8 years of drinking 
with consumption of about 124.6 oz of alcohol each week before admission [31].   
Women in the group of recovery subjects had a mean duration of drinking problem of 
13.4 years and were consuming 110.1 oz of alcohol each week when they were 
alcoholics [31]. Data collected from the women admitted in the recovery group 
showed that on an average these women had abstained from alcohol for about 8.3 
years [31]. It was seen that of women in the non-alcoholic group, 110 women 
reported no regular consumption of alcohol [31].  
The study results showed that among women who belonged to the treatment group, 
BMD was lower at femoral neck (7.7%) and lumbar spine (6.3%) when compared 
with non- alcohol drinking women [31].   1, 25-dihydroxyvitamin D levels were 
measured in women who participated and results were obtained in mean and 
adjusted for age [31]. It was noted that women undergoing treatment had low levels 
of serum vitamin D as compared with non-alcoholic women, though there was no 
significant difference between serum vitamin D levels in the non-alcoholic group and 
recovery group women [31]. This study also predicted the relation between alcohol 
consumption and fractures. Results of the study showed that 60.5% women in the 
treatment group and 63.5% women in the recovery group had reported a minimum of 
1 fracture in their lifetime [31]. By contrast, women who belonged to the non-
alcoholic group had 36.5% women who reported fractures [31]. This study 
complements the above findings by providing pilot data relating to another modality 
of bone quality as assessed by heel ultrasound. 
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1.14.2 Alcohol abuse in New Zealand and elsewhere 
It has been observed that young adults are more prone to drinking alcohol and often 
happen to binge drink. Binge drinking can be defined as consumption of more than 5 
drinks at a single occasion [32]. Many surveys had been conducted on the 
prevalence of alcohol abuse in young adults across the world and a related survey 
was conducted in the US [33]. The national survey on drug use and health (NSDUH) 
is the longest survey that provides proof on binge drinking through the collected 
samples for years from 1979 to 2006 [33]. The survey was conducted on young 
group people aged 12-34 years who were divided in 5 different groups as: 12 to 14, 
15 to 17, 18 to 20, 21 to 23 and 24-34 as a reference population [33]. The survey 
includes young adults from both sexes [33].  It was observed that men belonging to 
age group 21-23 had the highest rate of binge drinking. The odd ratios (OR) of 
alcohol abuse for this age group was 2.1 [33]. Results were different for female 
group in these categories. For females belonging to the age group 21-23 and 18-20 
the odd ratios were approximately 1.0 for constant number of years [33]. The odds 
ratio was observed for all the categorised age group vs 24-34 group of reference 
population [33]. For the females who belonged in the age group  15-17, the odd ratio 
was observed in the range of 0.2 to 04 , while those who belonged to age group of 
12-14, an odd ratio of 0.01 to 0.14 was noted [33]. The survey results state that 
relative risk of binge drinking was lower in young adults below 20 years of age. This 
has been attributed to the fact that any regulations and rules have been slated for 
alcohol consumption below 21 years of age and seems to be working as per the 
results of the survey [33].  Another issue which was highlighted in this survey was an 
increasing trend of alcohol and binge drinking in young females [33].  
 
There are fewer data available in the form of surveys on alcohol consumption and 
the data that is available is mostly for large economies like the US, UK and to some 
extent for Australia. But, for the population in New Zealand, a minimal quantity of 
data on alcohol consumption patterns is available for review [34]. One such study 
was conducted to report the trends of alcohol drinking in the New Zealand population 
taking into account data from surveys conducted in 1995, 2000 and 2004 [34]. 
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Households were selected from households who participated in 1995, 2000 and 
2004 surveys and a random based selection method was used. Survey results 
showed no significant difference in the number of male drinkers in year 1995 and 
2000 [34]. Results suggested that female drinkers had increased in number among 
women aged between 14-17 years [34]. Results also show that heaviest female 
drinkers of the group were in the age group 20-24 and 30-39 years. 
 
A history of NZ shows that NZ had a culture of alcohol drinking. According to the 
sociology report of 2010, binge drinking has increased in women to the same extent 
as men. The reasons for these changes might include factors such as an increase in 
the number of hospitality outlets where late night drink and parties are organised, 
changing and emerging role of women and liberalization of the liquor law [35].  
Another survey conducted in 2009 showed that of young adults of the age group 16-
17 years, 9% females and 15% males are involved in chronic alcohol consumption 
on a weekly basis [35].  
 
A web based survey was conducted on university going students in 5 NZ universities 
[36]. Samples were collected randomly from students of age groups 17-25 years who 
were full time university students [36].    430 Maori and 430 Non Maori students were 
invited from each university [36]. Questions were asked to participants about the 
number of time they engaged in binge drinking for last 1 year. Binge drinking was 
defined as more than 4 drinks for women and more than 6 drinks for men at one time 
[36]. Questions were also asked regarding any alcohol related issue/problem they 
faced [36]. Out of the students who participated, the majority of students were of 
European origin (71%), while 15% were Maori and the remainder were of other 
ethnicity [36].  The result of the survey showed that 88% of both men and women 
were involved in binge drinking for past 1 year [36].   Hence a review of the effect of 
alcohol on bone health is timely. 
 
 
 
 
31 
 
 
 
1.14.3 Effect of Alcohol on bone: 
Alcohol has both positive and negative effect on bone depending on consumption.  
Alcohol consumption can be divided in 3 sections: light, moderate and heavy [37]. 
There are several definitions and a fixed quantity is not defined to characterize the 3 
[37].  However, one study was conducted on alcohol and its effects on bone and 
defined the 3 consumptions in the following ways [37]: 
a. Light alcohol consumption: 1-10 g of ethanol/day 
b. Moderate alcohol consumption: 11-30g of ethanol/day 
c. Heavy alcohol consumption: more than 30 g of alcohol/day. 
 
Effect of light and moderate alcohol consumption: 
At least one study has showed that consuming small amounts of alcohol (wine) is 
associated with positive effects on BMD of the lumbar spine [37]. The effect of 
alcohol are dependent on age, sex, hormonal factors and beverage consumed [38]. 
A further study showed that post- menopausal women drinking 11-29 g (moderate) 
alcohol per day had increased BMD at the trochanteric site when compared with 
non-drinkers [38]. By contrast a further study showed that when a pre-menopausal 
women consumed 5-24 g of alcohol/day, the risk of fracture is increased [39]. With 
low alcohol consumption, BMD is typically increased. This is mirrored by BTM 
changes [39].  
 
1.14.4 Effect of alcohol on bone turnover: 
   
In long term consumption of alcohol, bone microarchitecture and remodelling 
processes are altered [39,40]. Fewer data are available on changes in bone 
microarchitecture after alcohol consumption, but  research shows that cortical and 
trabecular thickness are decreased along with decreased bone formation rate in 
subjects with alcohol induced bone disease [39,40]. 
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The available literature on bone and alcohol effects shows that the bone formation 
rate is decreased and bone resorption rate increased in subjects chronically 
consuming alcohol (120-150 g/day) [39,40]. A decrease in the rate of bone formation 
can occur because of inhibition of proliferation and activity of osteoblasts [39-40]. 
Some studies also show an increase in bone resorption markers, but less data is 
available [39, 40].  Consumption of alcohol in a chronic or high amount can also lead 
to an increased risk of fractures. People consuming about more than 100 g of 
ethanol per day have high reported rates of skeletal trauma and vertebral fractures 
[39, 40]. 
 
Though the effect of alcohol on bone is not completely clear, they can be divided into 
direct and indirect mechanism of action, listed below. 
 
Indirect mechanism of action: 
 
Body composition: 
a. Leptin: Leptin is a protein that is secreted by white adipose tissue. Studies 
shows that leptin regulates bone mass and has the ability to decrease bone 
mass through the CNS. Study results suggest that alcohol consumption 
decreases leptin and modifies the balance between adipogenesis and 
osteogenesis [39, 40].  
b. Cell differentiation:  Studies show that alcohol consumption causes a 
decrease in cell recruitment required for the osteoblast lineage when 
compared with samples from non-alcoholic subjects [39, 40].  
c. Vitamin D and PTH: Few studies are conducted on effect of alcohol on 
Vitamin D and PTH levels but some data suggest that PTH levels and vitamin 
D levels in the body decreases [40]. PTH plays a pivotal role in vitamin D 
activation and vitamin D has a positive effect on osteoblast differentiation and 
function [40].  Thus, chronic alcohol consumption decreases serum level of 
vitamin D [40] 
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d. Calcitonin: Some studies report that with moderate consumption of alcohol, 
calcitonin levels increases [40]. Calcitonin is a thyroid hormone that inhibits 
bone resorption [40]. 
e. Sex steroids: A few studies show a reduction in serum estradiol levels in 
females [40]. Low serum estradiol acts as a major factor in ethanol-induced 
bone loss [40].  Study results also suggest that consumption of low /light 
alcohol can increase serum estradiol levels [40]. 
 
 
 
Direct mechanism of action : 
 
a. Osteoblasts and osteoclasts: Studies report that alcohol causes a decrease 
in activity and differentiation of osteoblasts [40]. Minimal data is available on 
effect of alcohol on osteoclasts.  
Osteocyte: Osteocytes play a pivotal role in bone remodelling process [40].  
Osteocytes also helps in preventing activation of osteoclast when dying 
osteocytes send signals to osteoclasts [40]. Studies conducted on animals 
shows that osteocytes are modified because of alcohol and BMD was noted 
to decrease as osteocyte apoptosis increased [40]. 
b. Wnt pathway/DKKI: Wnts are glycoproteins. The most common pathway for 
activation of Wnt is Wnt/β pathway [40]. The pathway is activated by binding 
of Wnt to a co-receptor [40].  Β catenin has an ability to affect the gene 
transcription by staying in the cytoplasm [40]. Β catenin has the capability of 
regulating genes involved in differentiation, proliferation and apoptosis of bone 
[40]. Alcohol tends to suppress the Wnt activation pathway thereby causing 
negative effects on bone [40].  
DKKI acts as an antagonist to the Wnt pathway and its levels are increased 
due to alcohol consumption and can cause apoptosis of bone cell [40]. 
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1.15 Summary: 
 
Thus, whether it be in a direct or indirect way, alcohol induces changes in bone 
health with far fewer data available in young alcoholic females than other groups. 
The aim of this thesis is therefore: 
1. To compare bone health among healthy women (controls) with women admitted to 
an alcohol dependence unit at Kenepuru hospital using a heel ultrasound machine, 
with administration of a questionnaire about risk factors for low bone density. 
 
2. To examine bone turnover in 10 premenopausal women at the start and end of a 5 
day admission to an alcohol detoxification unit to assess changes on bone turnover. 
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Chapter Two: Methods 
 
2.0 Introduction: 
This research was conducted at the alcohol dependence unit based at Kenepuru 
hospital, Porirua.  Kenepuru Hospital was chosen because there is an independent 
drug and alcohol dependence unit with a high rate of admissions and dedicated 
junior medical staff. 
 
 
Figure 7: KENEPURU hospital 
 
The alcohol withdrawal services provided at CCDHB is a residential based program 
lead by Medical Director Dr. Geoff Robinson. Patients may self-refer or be referred 
by a clinician. The unit has 4 beds dedicated to the alcohol detoxification 
programme. Both male and females can be enrolled into the unit for the 
detoxification program. They are typically admitted for a 5 day period and many of 
them have further rehabilitation thereafter. 
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2.1 Specific Research and Objectives: 
In this research study, we considered only female participants enrolled in the 
detoxification program; we did not include males admitted to the unit as far more  
data and research articles are available relating  alcohol consumption and its effect 
on bone in men. There were about 130 admissions to the alcohol detoxification unit 
over the last year and managers  have predicted a total admission number of 150 for 
this year  inclusive of both male and female participants. In 2011, the numbers of 
female participants at the unit were 63 (48%), while the number of males was 67 
(52%).  
Age distribution is presented graphically in Figure 8 which shows the age distribution 
of admissions to the Unit during 2011, and demonstrates a wide age range of 20 – 
80 years. 
 
Figure 8: Graphical representation of Age distribution 
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The main aims of conducting this study were: 
 
1. To report  bone turnover in a group of women with alcohol dependence at 
admission to an alcohol dependence unit and after 5 days of abstinence from 
alcohol 
2. To examine bone health as assessed by heel ultrasound  at different ages 
among alcoholic females (premenopausal, menopausal, postmenopausal) 
and to compare the results with a group of healthy control women who also 
completed a questionnaire detailing lifestyle factors for bone health. 
 
2.2 Ethical considerations and Recruitment procedures: 
Ethics approval was sought and gained from Central Health and Disability Ethics 
Committee. 
Women were typically admitted to the alcohol dependence unit for a 5 day stay, with 
admissions anticipated at least one week in advance. Hence the researcher travelled 
to the unit each week to explain the study and after obtaining informed consent, to 
administer the questionnaire and perform the heel ultrasound scan. Staff at the unit 
were briefed about the study before it commenced and were consulted before any 
subject was approached to confirm that they were medically fit to be approached. 
Blood samples were taken on suitable subjects who had given informed consent by 
medical staff when routine blood tests were collected on admission and discharge. 
 
Participants were briefed about the study and were asked their willingness to 
participate. If they agreed, they were given a patient information sheet which 
contained detailed information about the study and were asked to sign the informed 
consent form. Once their consent was obtained, participants were asked to fill in a 
questionnaire. 
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2.2.1 Questionnaire: 
The research was conducted using a questionnaire based method. Subjects were 
asked to complete a detailed questionnaire starting with baseline data regarding their 
height and weight, their date of birth, GP’s name. 
 
Next, they were asked to complete set of 19 questions which were divided into 3 
sections:  
a. Questions related to alcohol and smoking, personal and family history 
of fractures and diseases:  
 
1. Whether they smoked or not, if they smoked the number of cigarettes, or 
amount of roll-up tobacco. Details of pipes or cigars smoked were asked. This 
datum was converted to pack years. 
2. Age at which they first started the consumption of alcohol. 
3. Amount and quantity of alcohol (options  given as shandy, low alcohol beer, 
lager, cider, low alcohol wine, wine, sherry, port, martini, cinzano, spirits or 
liqueurs). This data was converted to units of alcohol consumed each week. 
4. Whether they experienced any falls in the last year. If yes, age, broken bone 
history, details of x-ray and name of the hospital and date of the broken bone 
was recorded. 
5. Family history of hip fracture was recorded. 
6. The participant was asked to name any long lasting illness which they were 
suffering from such as overactive/ underactive thyroid gland, diabetes I, 
asthma, bronchitis, Rheumatoid arthritis and Coeliac disease. 
7. Menopausal history of the participants was also recorded and the date was 
noted if the patient had ceased menstruating. 
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b. Questions related to physical exercise and medications: 
 
8. Questions related to physical exercise were also asked. The exercise related 
questions were divided into 3 parts: brisk pace walking (number of days and 
time spend in doing the same), moderate physical exercise (number of days 
and time spend doing the same) and vigorous physical exercise (number of 
days and time spend doing this). 
9. Subjects were asked to describe their regular physical activity. They were 
given 5 options and were asked to select one which suited them the most. 
10. List of any type of medications which the subject had been taking was noted. 
 
 
c. Questions related to dietary calcium intake: 
 
The last section of the questionnaire was based on the dietary calcium intake of the 
subject. The information gathered was used to estimate a daily dietary calcium 
intake and for this reason food frequency questions were asked only about calcium 
rich food and drinks.  
11. In this section, they were asked to give the intake of total amount of milk 
consumed throughout the day. 
12. Subjects were asked to select 1 of the options out of none, once a month, 
once every 1-2 weeks, 1-22 days/ week, 3-5 days/week and every day for 
describing their intake of tea, coffee, any other milk drinks like Milo, Bournvita, 
Horlicks, hot chocolate etc. and milk alone. Along with this, subjects were 
asked to select the type of milk they consumed viz. none, liquid milk (whole, 
semi-skimmed, skimmed, UHT, sterilised and powdered made-up), tinned 
milk and powdered milk. 
13. In the diet section, questions were also asked describing the amount of 
consumption of bread, desserts made with milk, cheese, cakes, scones, 
biscuits and green vegetables.  
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Subjects were asked to select of the options from none, once a month, once 
every 1-2 weeks, 1-22 days/ week, 3-5 days/week and every day. This 
information was converted to dietary calcium intake per week. 
 
 
2.3 Heel Ultrasound: 
Once the questionnaire was completed, a heel ultrasound was performed on the 
subjects using a GE Achilles+ heel ultrasound machine. The GE Achilles+ heel 
ultrasound machine uses BUA, SOS and Stiffness Index (SI) as parameters to 
display the result, as shown below. It also gives a T-Score and a Z-Score which 
helps in identifying the risk of fracture for that particular subject as per WHO 
standards. 
 
Quality Assurance (QA) was performed of the machine before each use using a 
phantom. Once this was completed, each subject was seated comfortably as shown 
in Figure 9, and asked to insert their bare heel into the machine after liberal 
application of alcohol gel.  Once positioned, the measurement section on the 
machine was selected and participant’s age and side of heel to be measured (left or 
right) was entered. The typical scan time was a few minutes. 
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Figure 9: Heel ultrasound scan 
 
Below are the steps provided by the manufacturer of the ultrasound machine which 
were to be followed while performing the heel ultrasound scan: 
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1. Position the device and person: 
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2. Entering information and application of alcohol: 
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3. Measuring the Heel: 
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4. Results: 
 
 
2.4 Pilot study: 
Before we started the main study, we performed a pilot trial measuring heel density 
on a group of healthy subjects using the heel ultrasound machine.  This was 
conducted on 10 participants at the clinical trials unit, level 8 at Wellington Hospital, 
and was undertaken to familiarise the researcher with the machine, and to assess 
whether any difference existed between left and right heel measurements to inform 
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whether both sides should be measured in the main study.  The data obtained was 
as follows: 
Table1: T-Score for pilot study 
 
Left heel T Score Right heel T Score Comparison between left 
and right 
0.7 0.3 Left predominant 
-1.1 -1.7 Left predominant 
-0.1 -0.6 Left predominant 
-1.6 -1.0 Right predominant 
-0.7 1.8 Right predominant 
-1.5 0.7 Right predominant 
0.7 -1.1 Left predominant 
-1.5 -1.5 NA 
0.9 0.8 Left predominant 
-0.8 -1.5 Left predominant 
 
According to these readings, left heel ultrasound T-score results were greater than 
the right heel ultrasound T-score results in 6 out of 10 participants, while for 3 
subjects, right heel ultrasound results were greater than the left heel and for 1 
subject left and right heel ultrasound data were similar. This pilot study suggested 
that given the variability it would be prudent to perform measurements on both sides 
and to take an average of the two readings. 
 
2.5 Measurement of controls: 
Heel ultrasounds results were compared firstly with the manufacturer reference 
database. However, since no local New Zealand referent data was available, we also 
performed heel ultrasound on 20 further healthy control women with no history of 
alcohol dependence who were closely matched in age to the cases admitted to 
Kenepuru.  
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Volunteers were recruited from the general nursing staff at Kenepuru hospital, who 
gave informed written consent after receiving the information about the study. The 
same lifestyle questionnaire was administered to compare prevalence of other 
possible lifestyle factors for osteoporosis that we hypothesized might cluster in 
women with alcohol dependence, including reduced levels of physical activity, 
smoking and a low dietary calcium intake. 
 
2.6 Blood sample collection: 
Routine measures of renal function (urea and creatinine) were performed in all 
women admitted to the unit; serum magnesium levels were also available in all 
admissions. Blood samples were collected on Day1 in a subset; serum procollagen 
type 1 N propeptide (s-P1NP) and serum C-terminal cross-linking telopeptide of type 
1 collagen (s-CTX)  were also taken. Samples were collected again on Day 5 for s-
P1NP and s-CTX. Blood samples of bone turnover were taken only for 10 women 
who were premenopausal and of European origin. This restriction was performed to 
minimise variability due to age; menopausal status; ethnicity and to increase the 
likelihood of detecting change in bone turnover marker status from day 1 to day 5. 
2.6.1 Sample segregation techniques: 
Different techniques/assays were performed to measure Vitamin D, PTH, s-CTX and 
P1NP in selected blood samples. The detailed methods are outlined below. 
 
a. Technique for s-CTX: 
s-CTX was isolated from blood using the  Roche Elecsys Beta-Crosslaps methd. The 
assay is specifically used for an octapeptide in –terminus of type I collagen which 
reflects the bone resorption mediated by the osteoclasts. Samples were collected 
fasting early in the morning because of significant diurnal variation which is blunted 
after fasting. The reference interval is less than 0.75 µg/L in fasting in early morning, 
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while the uncertainty of measurement is 0.01µg/L for less than 0.1 µg/L and 10% for 
more than 0.13 µg/L 
b. Technique for P1NP: 
P1NP was isolated from blood with the Roche Elecsys 2010 method.  P1NP is a 
bone formation marker which is a specific indicator of type I collagen disposition. 
P1NP is released as a trimeric structure, but it degrades into a monomer. P1NP is 
used to assess the response to osteoporosis treatment because it increases in state 
of high bone turnover. The reference interval for P1NP is not specific as it is age 
related.  
 
c. Technique for Vitamin D (25-Hydroxycholecalciferol): 
Vitamin D was separated from blood using a radioimmuno assay (RIA) after the 
extraction  with acetonitrile.  Below is the suggested reference range: 
a.  Optimal target range for bone health : 50-150nmol/L 
b. Moderate to severe deficiency : < 225 nmol/L 
c. Mild deficiency : 25-50 nmol/L 
 
d. Technique for Parathyroid hormone (PTH): 
PTH was separated from blood using an Elecsys assay. The elecsys assay employs 
a sandwich test principle in which a biotinylated monoclonal antibody reacts with N-
terminal fragment and a monoclonal antibody labelled with Ruthenium complex 
reacts with C-terminal fragment.  The measuring range specified is 1.20-5000 pg/mL. 
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Chapter Three: Results 
3.0 Characteristics of population: 
a) Women admitted to alcohol dependence unit 
Table 2: Characteristics of women admitted to the alcohol unit 
 N Minimum Maximum Mean Std. 
Deviation 
Age at 
admission 
20 27 67 45.2 9.0 
Age of 
starting 
alcohol 
20 12 41 16.3 6.2 
Dietary Ca 
(mg/week) 
20 849.9 19872.3 4624.1 4202.7 
 
Table 2 shows the summary characteristics of women admitted to the alcohol 
dependence unit. Among the 20 women who had been admitted to the unit for 
alcohol detoxification, the mean age was 45.20 (SD = 8.97) years. Women reported 
that they had been drinking alcohol for a mean of 16.25 (SD = 6.61) years prior to 
admission to the unit. The mean alcohol consumption per day was 19.80 units with a 
standard deviation of 9.90.  Dietary calcium intake was very variable; the range was 
(849.90-19872.30) mg weekly. The mean dietary calcium intake per week was 
4624.08 mg.  
  
Nine women (45 %) reported that their periods had stopped by the time of interview. 
Fifteen women (75 %) were current smokers; 85 % were ex-smokers and 15 % were 
lifelong non-smokers. Among smokers the mean pack years were 18.60. Fifteen (75 
%) women reported at least one fall in the previous year; 7 women reported a 
previous fracture. 
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2 (10%) women out of 20 reported any vigorous physical activity in the preceding 
week. 5(25%) women out of 20 reported any moderate physical activity in the 
previous week. Seven women out of 20 (35 %) reported a co-morbidity; in 4 cases 
this was a diagnosis of depression, but 2 women reported seizures, 4 a history of 
bronchitis  and one a history of cardiovascular disease. Others reported 
degenerative lumbar spine disease and non-specific abdominal pain. 
 
b) Healthy controls 
Table 3: Characteristics of healthy women as controls 
 
 N Minimum Maximum Mean Std. 
Deviation 
Age at 
admission 
16 21 67 42.3 130 
Age of 
starting 
alcohol 
14 12 21 16 2.42 
Dietary Ca 
(mg/week) 
16 705.9 8164.0 3503.8 2187.4 
 
 
Table 3 shows the summary characteristics of healthy women who had been 
included as controls in the study. Sixteen healthy women participated in the study. 
The mean age was 42.31 (SD = 12.95) years. Women reported that they had been 
drinking alcohol for a mean of 16 (SD = 2.42) years. The mean alcohol consumption 
per day was 1.77 units with a standard deviation of 2.74. Dietary calcium intake was 
51 
 
 
 
very variable in the range of (705.90 – 8164.00) mg weekly. The mean dietary 
calcium intake per week was 3503.83 mg. 
Six women (37.5%) reported that their periods had stopped by the time of interview. 
One woman (6.3 %) was a current smoker; 7 women (43.8 %) were ex-smokers and 
9 women (56.3 %) were lifelong non-smokers. Among smokers the mean pack years 
were 6. Four (25%) women reported at least one fall in the previous year; 7 women 
reported a previous fracture. 
Nine (56.5%) women out of 16 reported any vigorous physical activity in the 
preceding week. Eleven (69%) women out of 16 reported any moderate physical 
activity in the previous week. Four women out of 16 (25 %) reported a co-morbidity; 
2 a history of bronchitis and one cardiovascular disease. 1 woman reported 
degenerative lumbar spine disease and non-specific abdominal pain. 
The significant differences in lifestyle factors likely to influence bone mass are age at 
admission, age of starting alcohol and dietary Ca intake as highlighted in Table 1 
and 2. 
3.1 Heel ultrasound (HUS) parameters: 
The heel ultrasound results among healthy controls and alcohol dependent women 
are shown below in Table 4 and displayed graphically in figure 10 
 
Table 4: HUS results of alcohol dependent women vs healthy controls 
 Alcohol dependent women Healthy controls 
 Mean SD Mean  SD 
BUA 107.38 14.63 121.16 27.28 
SOS 1550.58 38.07 1570.6 44.51 
SI 85.65 18.42 95.53 18.66 
T score -1.09 1.42 -0.31 1.40 
Z score -0.44 1.29 0.28 1.41 
. 
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Of the 20 women admitted to the alcohol detoxification unit, those with a |T| score 
classed as normal was 9 (45%); with a T score between -1 and -2.5 was 6 (30%) 
and lower than -2.5 was 4. (20%) 
The mean average SOS for the 20 women admitted to the unit for both heels was 
1550.58 m/sec and the mean average BUA was 107.39 dB/MHz, while the mean 
average SOS for the 16 women who participated in the study as controls for both the 
heels was 1570.62m/sec and mean average BUA was 121.17dB/MHz. 
However, the crude difference in mean value for each of these variables between the 
alcohol dependent women and the controls was not statistically significant as shown 
in the below table: 
 
Table 5: Difference in mean values of HUS outcomes between both the groups 
HUS 
outcomes 
Df F P value 
Avg BUA 1 0.77 0.38 
Avg SOS 1 0.03 0.86 
Avg T Score 1 0.40 0.53 
Avg Z Score 1 0.34 0.56 
Avg SI 1 0.36 0.54 
 
Thereafter, the values for all 36 women were combined into one data set to increase 
statistical power when evaluating relationships between alcohol consumption and 
bone quality. The mean values of each variable in the combined data set are shown 
below; results are plotted graphically to demonstrate normality. 
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Table 6: Mean value for both groups for HUS outcomes 
 Alcohol dependent group Healthy women 
Heel Ultrasound 
Parameters 
Mean  SD  Mean  SD  
Avg BUA 107.39 14.63 121.17 27.28 
Avg SOS 1550.58 38.07 1570.62 44.51 
Avg T score -1.10 1.422 -0.32 1.40 
Avg Z score -0.45 1.29 0.28 1.41 
Avg SI 85.66 18.42 95.53 18.66 
 
The age bands with the HUS outcomes were assessed together for both the groups 
to increase the number and power of the data. The mean value by age bands for the 
grouped women was: 
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Table 7: Mean value of HUS outcomes as per age bands for both the groups 
together   
HUS 
outcomes 
Mean SD P value 
Avg BUA  
0-36 
37-44 
45-50 
51+ 
 
114.38 
122.65 
100.48 
117.65 
 
7.96 
12.65 
13.42 
39.66 
.176 
Avg SOS 
0-36 
37-44 
45-50 
51+ 
 
1552.25 
1595.08 
1542.96 
1547.29 
 
27.28 
39.16 
34.71 
47.69 
0.023 
Avg T Score 
0-36 
37-44 
45-50 
51+ 
 
-0.70 
0.63 
-1.62 
-1.34 
 
0.65 
1.24 
1.36 
1.37 
0.002 
Avg Z Score 
0-36 
37-44 
45-50 
51+ 
 
-0.62 
1.07 
-0.91 
0.03 
 
0.70 
1.31 
1.41 
1.22 
0.007 
Avg SI 
0-36 
37-44 
45-50 
51+ 
 
90.77 
108.22 
78.88 
81.87 
 
8.47 
16.50 
17.72 
18.06 
0.002 
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Figure 10: Histogram to show Distribution of BUA among women admitted to the 
alcohol dependence unit 
 
Figure 11: Histogram to show Distribution of BUA among women enrolled in the 
control group 
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Figure 12: Histogram to show Distribution of SOS among women admitted to the 
alcohol dependence unit 
 
 
Figure 13: Histogram to show Distribution of SOS among women enrolled in the 
control group 
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Figure 14: Histogram to show Distribution of T Score among women admitted to the 
alcohol dependence unit 
 
 
Figure 15: Histogram to show Distribution of T Score among women enrolled in the 
control group 
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Figure 16: Histogram to show Distribution of Z Score among women admitted to the 
alcohol dependence unit 
 
 
Figure 17: Histogram to show Distribution of Z Score among women enrolled in the 
control group 
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Figure 18: Histogram to show Distribution of SI among women admitted to the 
alcohol dependence unit 
 
 
 
Figure 19: Histogram to show Distribution of SI among women enrolled in the control 
group 
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3.2 Menstruation status and association with heel ultrasound outcomes: 
We assessed whether menstrual status was a determinant of heel ultrasound 
variables in this dataset. We analysed this parameter of whether ‘still having periods 
= y/n’ with all the 5 heel ultrasound outcomes using Analysis of variance (ANOVA) 
for all 36 women together as a cohort for different age bands. After adjustment for 
age, by analysing in predefined age bands, we found higher values among women 
who still reported menstruation, as shown below in Table 8. 
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Table 8: Mean HUS values by menstrual status 
Age bands Mean SD Df F P value 
Avg BUA  
0-36 
37-44 
45-50 
51+ 
 
114.33 
125.15 
98.08 
118.1 
 
8.51 
8.71 
12.38 
3 7.74 0.002 
Avg SOS 0-
36 
37-44 
45-50 
51+ 
 
1554.90 
1593.73 
1530.28 
1611.90 
 
27.90 
44.21 
37.52 
3 3.68 
 
0.03 
 
Avg T 
score 
0-36 
37-44 
45-50 
51+ 
 
 
-0.65 
0.73 
-2.02 
0.75 
 
 
0.68 
1.22 
1.37 
3 6.86 0.003 
Avg Z 
score 
0-36 
37-44 
45-50 
51+ 
 
 
-0.57 
1.16 
-1.29 
1.65 
 
 
0.73 
1.30 
1.44 
3 5.84 0.006  
Avg SI 
0-36 
37-44 
45-50 
51+ 
 
91.50 
109.50 
73.80 
110.00 
 
8.76 
16.32 
17.67 
3 6.73 0.003 
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We used an independent T-test to calculate the effect of smoking status on HUS 
outcomes and found significant differences with lower values among women who had 
ever smoked for Avg SOS (p value = 0.02) and for Avg SI (p value = 0.04) (Table 9)  
 
Table 9: Means between subjects and controls according to smoking status 
 
 T Df p 
value 
Avg 
BUA 
0.114 33 0.91 
Avg SOS 2.390 33 0.02 
Avg T 
score 
2.004 33 0.05 
Avg Z 
score 
1.764 33 0.08 
Avg SI 2.056 33 0.04 
 
 
For the variables ‘family history of hip fracture’ and ‘still smoked regularly’, we showed 
no significant effect on the mean for all the 5 outcome variables Avg BUA, Avg SOS, 
Avg T Score, Avg Z Score and Avg SI. 
 
3.3 Bone Turnover markers: 
Bone turnover markers were measured among a subgroup of premenopausal 
women admitted to the alcohol dependence unit. The aim was to obtain bone 
turnover samples for 10 women from the subjects group. However, at the time of this 
data set construction, we had available only the results for 6 women. 
Table 10 shows the mean (SD) values for day 1 P1NP, day 5 P1NP, day 1 s-CTX, 
day 5 s-CTX.: 
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Table 10: Mean (SD) bone turnover markers: 
 
Paired Samples Statistics 
 
Mean N 
Std. 
Deviation 
Std. Error 
Mean 
Pair 1 Day 1 P1NP (Ref 
range: 15-60 µg/L) 
23.08 6 9.52 3.88 
Day 5 P1NP 27.88 6 8.03 3.28 
Pair 2 Day 1 s-CTX(Ref 
Range : &lt;0.75 
µg/L) 
.14 6 .07 .029 
Day 5 s-CTX .13 6 .08 .03 
 
The mean value for day 1 P1NP was 23.08µg/l with SD = 9.52; while the mean value 
for day 5 P1NP was 27.88µg/l with SD of 8.03. 
The mean value for day 1 s-CTX was 0.14µg/l (SD = 0.07); while the mean value for 
day 5 s-CTX was 0.13µg/l (SD = 0.08). These differences were significant, even in 
this small pilot study, for PINP but not CTX. 
 
Table 11: Mean difference between Day 1 and Day 5 Bone markers 
 
 Mean SD t Df p value 
Day 1 P1NP 
– Day 5 
P1NP 
-4.8000 4.3731 -2.689 5 0.043 
Day 1 s-
CTX – Day 
5 s-CTX 
0.00833 0.10068 0.203 5 0.847 
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3.4 Blood Samples: 
Blood samples were obtained from 20 women who participated in the subjects group 
who were admitted at the alcohol detoxification unit. Creatinine, Magnesium, PTH 
and Vitamin D levels were checked from the blood samples obtained. 
Relationships between these biochemical values and the heel ultrasound outcomes 
BUA, SOS, T score, Z score and SI were investigated, but none were significant. 
This may reflect the small sample size and limited power for this aspect of the study, 
particularly as results were often missing from the clinical system. 
 
Table 12: Relationship between biochemical values and HUS outcomes 
 Avg BUA Avg SOS Avg T 
score 
Avg Z 
score 
Avg SI 
Creatinine 0.11 
P value = 
0.65 
-0.12 
P value = 
0.61 
-0.004 
P value = 
0.98 
-0.08 
P value = 
0.74 
-0.009 
P value =  
0.97 
 
Magnesium -0.08 
P value = 
0.75 
0.14 
P value = 
0.59 
0.03 
P value = 
0.90 
0.09 
P value = 
0.71 
0.03 
P value =  
0.88 
PTH -0.03 
P value = 
0.95 
-0.06 
P value = 
.0.91 
-0.05 
P value = 
0.93 
-0.20 
P value = 
0.73 
-0.04 
P value =  
0.93 
Vit. D -0.77 
P value = 
0.22 
-0.29 
P value = 
0.70 
-0.51 
P value = 
0.48 
-0.43 
P value = 
0.56 
-0.52 
P value = 
0.48 
 
Please note that bone turnover markers and blood samples had not been obtained 
for the women included in the control group 
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3.5Summary: 
In conclusion, the main findings of the study were as follows: 
a. The mean alcohol content/day  in women admitted to the alcohol detoxification 
unit was 19.80/day compared to women who participated in the control group 
(1.77/day) 
 
b. In women admitted to the alcohol dependence unit, the mean average 
outcome for BUA, SOS, T score, Z score and SI was low as compared to 
women participated in control group; the mean Z Score (age related outcome) 
was observed to be lower in women admitted to the alcohol unit with a value of 
-0.44; whereas, the mean Z score in control group women was 0.28. 
 
c. 7 out of 20 women (35%) admitted to the alcohol dependence unit had 
reported a history of fracture ; while 7 out of 16 healthy control women (43.8%) 
had reported a history of fracture, suggesting that healthy women at risk of 
osteoporosis may have volunteered to participate in this study as they were 
interested in their risk.  
 
 
d. 15 out of 20 women (75%) with alcohol dependence had reported falls in the 
preceding year before admission to the unit, whereas only 4 women out of 16 
(25%)  who participated as controls in the study had reported falls, highlighting 
the high falls risk in alcoholics. 
 
e. Dietary calcium intake in both the groups was similar but below the 
recommended weekly intake of 5600 to 7000 mg weekly; the dietary intake 
among the alcoholic women was 4624.80 mg/week while the calcium intake in 
the healthy control group was 3503.83 mg/week. 
 
f. Women admitted to the alcohol unit were less physically active than women 
who participated in the control group. Five out of 20 alcohol dependent women 
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(25%) performed regular moderate physical activity and 2 out of 20 women 
(10%) performed regular vigorous physical activity. By contrast, 11 out of 16 
healthy control women (68.75%) performed regular moderate physical activity 
while 9 out 16 (56.25%) performed regular vigorous physical activity. 
 
g. Women who had ever smoked regularly have significantly lower Avg SOS and 
Avg SI results than lifelong non-smokers.  
 
h. After adjustment for age, by analysing in predefined age bands, HUS results 
were significantly higher among women who still reported menstruation when 
compared with women whose periods had stopped 
 
i. Even in this small pilot study, there was a significant rise in the bone formation 
marker P1NP between the day of admission to an alcohol dependence unit 
and after 5 days of abstinence 
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Chapter Four: Discussion 
4.0 Findings: 
We have performed a study administering a lifestyle questionnaire and performing 
heel ultrasound in two groups of women; women with a history of alcohol 
dependence and staff members from the same unit. The questionnaire we 
administered detailed age, personal and family history of fracture, cigarette smoking 
(pack years), alcohol history (duration and level of drinking; type of alcohol 
consumed), physical activity, dietary calcium intake (food frequency questionnaire), 
past medical history (to elicit information on possible other secondary causes of 
osteoporosis e.g. insulin dependent diabetes, hyperthyroidism), drug history and 
reproductive history. 
 
As anticipated, we found a number of lifestyle differences other than levels of alcohol 
consumption between the two groups studied. That the mean age at admission for 
alcoholic women was 45.20 years, while that in healthy women was 42.50, so 
matching by age was reasonable. The mean age of starting drinking alcohol was 
16.25 in alcoholic women, which was similar to healthy women. Dietary Ca intake 
and physical activity levels were higher in healthy women when compared with 
women admitted to the alcohol unit. As expected, there was a significant difference 
in the mean alcohol content/day in women admitted to the alcohol unit (mean intake 
was 19.80 units/day) to women participated in control group (mean intake was 1.77 
units/day).  
 
Fifteen women out of 20 admitted to the alcohol unit had reported falls in the 
preceding year with 7 women (35%) having fracture history. These results may be 
compared with results found in one study conducted on alcoholic men with an 
ethanol consumption of more than 150g/day. 81 men participated in the study and in 
those men, the prevalence of fracture was 49.3% mainly rib fracture [41]. When our 
study results were compared with similar studies conducted on men and women we 
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found a similar percent of people suffering from fracture risk. In our group of 
alcoholic women, 6 women out 20 had osteopenia (30%), whereas only 25% 
controls were classified as osteopenic. Though other studies conducted on 
alcoholics reported a significant difference in fracture history  between alcoholics and 
controls [41]; this is in contrast to our own study results; even in our control 
population, 7 out of 16 women (43.8%) had reported a previous history of fracture. 
This may reflect an awareness of osteoporosis risk in our control group, who 
volunteered for this study for this reason. Among controls, only 4 women out of 16 
(25%) had reported a fall in the preceding year of admission. 
 
We evaluated the dietary Ca intake /week for both groups and found that dietary Ca 
intake in both the groups was below the recommended levels of 6300 to 8000 mg/ 
week. Dietary Ca intake in the subject group was 4624.80 mg/week while Ca intake 
in the control group was 3503.83 mg/week i.e lower than among the alcoholic group.  
 
The drug history we took showed that 1 out of 20 alcoholic women (5%) were on 
steroids at admission to the alcohol detoxification unit, while 2 out of 20 women 
(10%)were on vitamin D supplements. In women enrolled in the control group, no 
woman was on any of these supplements. Blood samples were obtained from 
women admitted to the alcohol unit to test  vitamin D and PTH levels.  According to 
national guidelines, a serum concentration of 25(OH)D is defined as insufficient if 
less than 50 nmol/L,  if less than 25 nmol/L it is classified as deficient and  severe 
deficient is defined as less than 12.5 nmol/L. Vitamin D levels were obtained only in 
4 subjects out of 20 (20%), a severe limitation of our study, and were in the range of 
11 to 70 nmol/L. The mean level of vitamin D was 46.50 nmol/L. Our study results 
were similar to other study results which showed that vitamin D levels were 
significantly deficient in alcoholics [42]. In a study conducted by Ulrich Bang et al., 
out of 146 participants enrolled (66 men and 80 women), the mean level of vitamin D 
was 47 nmol/L [42]. In this group, vitamin D levels were comparatively higher in 
participants who were on vitamin D supplements [42]. Unfortunately vitamin D levels 
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were not measured in participants who were on oral vitamin D supplements in our 
study.   
 
Another lifestyle factor that plays an important role in bone health is physical 
exercise. We assessed physical activity levels for both the groups and found that 
women admitted to the alcohol unit were less physically active than women who 
participated in the control group. 5 out of 20 alcoholic women (25%) performed 
regular moderate physical activity and 2 out of 20 women (10%) performed regular 
vigorous physical activity. By contrast, 11 out of 16 control women (68.75%) 
performed regular moderate physical activity while 9 out 16 performed regular 
vigorous physical activity. 5 women out of 20 (25%) alcoholic women reported being 
regularly physically active for past 6 months and 13 out of 16 (81.25%) women in the 
control group were regularly physically active in the past 6 months. Sampson [46] 
showed that among women who were chronic alcohol drinkers and who undertook 
some regular physical activity, BMD was higher as compared to non-physically 
active alcoholic women [46]. Also, when he compared the results with healthy 
controls who undertook regular physical activity, BMD was slightly higher than in the 
alcoholic women who undertook no physical activity [46].   
 
Preclinical studies have been performed on alcohol fed animals to evaluate the effect 
of exercise on them [47]. The study results showed that exercise did not lessen the 
side effects caused by the alcohol on the bone [47]. Though there is less literature 
available on whether exercise can improve bone density in alcoholics, some studies 
showed that any mechanical stress either by doing any physical exercise or by 
carrying heavy weights can increase bone density [48].  
 
Earlier studies and literature available shows that most of the studies on effect of 
alcohol on bone mineral density have been performed in men. A study conducted by 
Mulleman et al compared the BMD in alcoholic patients and healthy men and they 
70 
 
 
 
observed that BUA, SOS and SI were higher in controls when compared with 
alcoholic patients [49].  
 
In summary the main aim of our study was ‘To compare bone health among healthy 
women (controls) with women admitted to an alcohol dependence unit at Kenepuru 
hospital using a heel ultrasound machine’. We performed a heel ultrasound scan for 
all the 36 participants (20 alcoholic women and 16 controls) and results were 
obtained on 5 parameters viz. BUA, SOS, T score, Z score and SI for both the heels. 
We added the results for both the heels and obtained average results for all these 5 
outcomes. It was seen that in general the mean average outcome for BUA, SOS, Z 
score and SI was low as compared to women who participated in control group. 
Further work in a larger study group is now indicated. 
 
4.1 Animal studies of alcohol and bone: 
As discussed in earlier chapters, osteoporosis is a disease which is defined as micro 
architectural deterioration of bone which thereby lowers the BMD [50]. This 
deterioration of bone can lead to fragility and fractures of bone [50]. There have been 
several studies published on the effect of alcohol on bone; in general the literature 
shows that moderate alcohol consumption is associated with an increase in bone 
strength whereas, chronic consumption of alcohol can decrease BMD and increase 
the chance of fractures. It is yet not known how alcohol causes bone loss. Many pre-
clinical studies have been performed to understand the mechanism and effect of 
alcohol on bone. This section discusses the findings of this area of research, and its 
possible relevance to our own study. One such study was conducted on long boned 
rats to check the effect of different concentrations of alcohol on them [50].  18 rats 
were evaluated in acute and chronic studies and were divided into 3 groups for both 
the studies [50]. In control animals (group A), normal saline was administered for 5 
days intraperitoneally while 20 % and 30% alcohol was administered to treated 
animals (group B) and (group C) [50]. The acute study was terminated after 6 days 
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of exposure while the chronic study was halted after 6 weeks of exposure to alcohol 
[50]. After the study was terminated, the femur and tibia were dissected from the 
body of the rats [50]. The results in the acute study showed that bone weight and 
strength increased at 20% alcohol exposure; whereas bone weight and strength 
decreased at 30% of alcohol exposure [50]. In the chronic study which was 
terminated after 6 weeks of treatment, study results showed that bone weight and 
strength decreased in both treated animal groups [50]. These results of the study 
suggested that bone strength and weight decreased as alcohol concentration is 
increased [50]. This may be relevant in understanding the aetiology of bone loss in 
chronic alcoholics. 
 
To understand more about the biological aspect of the effect of ethanol, bone 
research has been undertaken and shows that there are many cytokines that play an 
important factor in bone resorption process; IL-6 is one of them [51]. Studies have 
shown that ethanol can lead to a rise in IL-6 gene expression in bone marrow [52]. A 
study was performed on mice based on a hypothesis that ethanol can cause bone 
loss as it has an ability to induce IL-6 mediated osteocalstogenesis [52].  To 
measure bone loss, DEXA was performed on the mice [52]. The mice were divided 
into IL6+/+ and IL6-/- groups [52]. The whole body BMD was reduced by 3.01 % in 
the ethanol-fed IL6+/+ mice, when compared with the control-fed IL6+/+ mice [52]. 
However, there was no significant difference between whole body BMD of IL6-/- 
mice for both alcohol fed and control fed mice [52]. The femoral BMD of both the 
groups of mice was also measured and it was observed that in alcohol fed 
IL6+/+mice BMD decreased by 5.37% and no difference was observed in IL6-/- mice 
in both the groups [52]. These results suggest that excessive abusive alcohol 
consumption can lead to increased bone loss and implicates IL-6 can cause bone 
loss when estrogen levels are low [52].  
 
Animal studies have also been performed to check whether chronic alcohol 
consumption can decrease the mineral constituents of bone.  
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As we know, bone is mainly composed of Ca and P [53]. At the time of menopause, 
estrogen levels in the women’s body decrease thereby causing an imbalance in the 
Ca and P concentrations in the bone [53].  Studies have shown that alcohol induced 
estrogen deficiency can lead to an imbalance in bone mineralisation thereby 
decreasing BMD [53]. In a study which was conducted on 54 rats,[53] rats were 
divided in 2 groups. Group 1 consisted of rats who had been ovariectamised with low 
estrogen levels, while group 2 consisted rats with ovaries not removed [53]. These 
were again divided and were fed 20% alcohol and control solution [53]. The results 
showed that the Ca and P concentrations in the bones extracted were decreased in 
the alcohol fed rats. It was also observed that there was a significant difference in Ca 
and P levels in estrogen deficient alcohol fed rats and control fed rats [53]. This 
study results also highlighted that when food and nutrients were fed to the rats, a 
significant increase in Ca and P was seen thereby improving the quality of the bone 
[53]. Other studies have  shown lower BMD  at the tibia and the femur in alcohol fed 
animals as compared to control  animals [54]. 
 
In addition to the studies above, research has been undertaken to check whether 
chronic alcohol use damages fracture repair properties and whether abstinence from 
alcohol improves bone quality and strength [55]. Research was conducted on 36 rats 
divided in 4 different groups: Group A and B were on a Lieber - Decarli liquid diet 
with either 36% ethanol or control diet [55]. AIN-93M ad libitum diet was given to rats 
in group C, and group D rats were fed with AIN-93M liquid ethanol diet [55]. The 
study results showed that rats in group C had a higher bending rigidity than group A 
(48%) and group B (47%) [55]. Group D rats had bone quality results similar to group 
C rats [55]. In group A and group B rats, the mineral constituent of bone was 16 % 
and 13 % respectively; while in group C and group D the mineral content was normal 
[55]. Thus, these study results suggested that the bone repair function was damaged 
in Group A rats (alcohol fed) as compared to their counterparts in group B who were 
kept on control liquid diet [55]. The results also suggested that after bone injury, if 
there is abstinence from alcohol the bone repair mechanism improved thereby 
improving bone quality [55].   
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Studies have showed that bone loss which occurs because of alcohol happens 
mainly because of an imbalance in the bone remodelling cycle [56]. Research shows 
that some inherited polymorphisms at particular gene loci can be a risk factor for 
post - menopausal osteoporosis [56].  A study had been conducted on rats to 
recognise changes in expression profiles for bone formation and bone resorption-
related genes [56].  Adult male rats included in the study were divided into 2 groups 
with either 1 week of treatment or 4 week of treatment. The rats were fed either 
binge alcohol or as saline-treated controls [56]. To measure the blood ethanol levels, 
NAD+ reduction assay was performed and to measure the biomechanical properties 
of lumbar vertebrae compressive strength tests were performed [56]. There was no 
significant decrease in BMD of vertebral cortical bone among rats treated with 
moderate binge alcohol as compared to controls [56]. In rats fed with chronic binge 
alcohol, a significant reduction in vertebral cancellous bone BMD was observed [56]. 
The compressive strength was also decreased in these rats when compared with 
controls [56]. This study also highlighted that bone formation markers gene 
expressions (eg. Alkaline phosphatase and osteocalcin) decreased after exposure to 
moderate binge alcohol consumption with a p value of 0.015 and 0.003 respectively 
[56].  For bone resorption markers (eg. RANKL); after moderate binge alcohol 
exposure the levels increased and normalised after chronic binge alcohol exposure 
[56]. This study demonstrated gene expression changes for both bone resorption 
and bone formation markers after exposure to binge alcohol treatment [56]. It 
suggests that bone loss due to alcohol intake may be a result of changes in 
expression of genes that plays an important role in the bone remodelling process 
[56]. 
 
 
4.2 Alcohol bone studies in men: 
Heavy alcohol can be a reason for secondary osteoporosis in men and thus research 
had been conducted to see how deleterious the effects of chronic alcohol are on 
men. In one study conducted on male chronic alcohol drinkers [57], 138 male 
subjects participated in the research. Patients included in the study  had 3 years or 
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more history of alcohol dependence. Alcohol content was calculated and heel 
ultrasound was performed [57].  20 patients were included in a lifestyle modification 
program for two and half months where they went into alcohol detoxification. 
Lifestyle modification of these 20 patients included increased levels of physical 
activity, dietary improvements, and general education programs. Chronic 
consumption of alcohol was associated with a decrease in BMD in older alcohol 
dependent people [57]. Lifestyle modification was seen to be beneficial and 
achievable.  
 
A study conducted by Kim et al [58] included 18 alcoholic men who consumed >= 40 
g of alcohol/day and 18 controls who consumed less than 20 g of ethanol/day and all 
of whom were ambulatory patients [58]. The study results showed that daily Ca and 
protein intake was the same in alcoholics and controls. Osteocalcin and vitamin D 
levels were higher in the control group than heavy drinkers [58]. The study results 
support the earlier discussed findings in pre-clinical studies.  
In an older population, the majority of fractures are because of falling. As discussed 
above, high consumption of alcohol leads to decrease in bone density and thus there 
can be a relation between alcohol intake and falls and fractures [59]. Furthermore, 
alcoholic intoxication is strongly associated with falling. At least one study suggest 
that excessive chronic alcohol intake is associated with a higher risk of hip fracture 
[60]. In the MrOS (Osteoporotic Fracture in Men study), 5995 older men above 65 
years of age with no hip replacement history were recruited. A questionnaire based 
method was used and questions detailing the alcohol type and amount, problem 
drinking, falls and fractures were asked. BMD was calculated using DEXA. The study 
results showed that light to moderate alcohol consumers were not at higher risk of 
falls and fractures while a history of chronic excessive consumption of alcohol led to 
an increased risk of falls and fractures [61]. Though there are only a few studies that 
compared excessive alcohol intake and fracture risk, the above suggest that there is 
a link, and this is mediated through a combination of falls and low BMD. 
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4.3 Alcohol bone studies in women: 
Research shows that women are at higher risk of suffering from osteoporosis than 
men. Lifestyle factors associated with alcohol dependence may be important; 
smoking and alcohol can decrease BMD [62], whereas lifestyle factors such as 
physical activity and high dietary calcium intake can improve bone health [63]. 
Educational programmes to modify lifestyle have been undertaken. A study was 
conducted on 669 healthy pre-menopausal women aged 15-35 years to evaluate the 
effect of educating about osteoporosis [64]. Women were asked to complete a 
questionnaire before the education program about BMD testing and osteoporosis 
and after the program [64].  Follow- up was at a year. The study results showed an 
increase in Ca intake, physical activity, vitamin D supplements and decrease in 
smoking and alcohol content after 1 year of follow–up [64]. The study results were 
similar to another study which was conducted on 263 pre-menopausal women who 
underwent an education programme about osteoporosis [65]. Both the studies 
showed that in women with normal BMD, there was no subsequent significant 
difference in Ca intake and physical activity before and after the education program, 
but in women with a low BMD, there was a significant increase in Ca intake and 
physical activity [64, 65].   
 
Several methods have been introduced to predict the risk of osteoporosis by 
measuring the BMD including DEXA and quantitative heel ultrasound. While several 
studies have evaluated one or the other technique, fewer studies have been 
performed to identify which is the best way to predict this fracture risk. One such 
study had been performed using a questionnaire based method and involving use of 
both the techniques (DEXA and QUS) to predict risk of fractures in 668 healthy 
women [66]. BMD was measured at the hip and lumbar spine by DEXA, while heel 
SI, BUA and SOS was measured using a heel ultrasound machine.  The study 
showed that 50 women out of 668 had low bone mass at the hip and 100 women out 
of 668 had low bone mass at the lumbar spine. 122 women had a low bone mass as 
assessed by SI and QUS. In total, there were 61 women who had decreased BMD 
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as measured by both DEXA and QUS. The factors associated with low bone mass in 
this study were: low body weight, late age at menarche (>15 years) and low levels of 
physical activity [66].   
 
Studies have also shown that side effects of alcohol are much greater physiologically 
in women than in men [68]. The negative consequence of heavy drinking includes 
alcohol related falls leading to injuries, heart disease and cognitive disease. In our 
study more than 50% of the women had experienced falls because of chronic alcohol 
consumption. Comorbidities are also more frequent; in the National Comorbidity 
study, comorbidities were higher in alcoholic women with 72.4% as compared to that 
in alcoholic men with 56.8% [68]. These comorbidities included depression and 
anxiety, as in our own study.   
 
4.4 Alcohol dependency in New Zealand: 
New Zealand, like other developed countries of the world faces the problem of 
chronic excessive alcohol consumption in society. It has been also observed that 
alcohol consumption is more common in the older population as compared to the 
younger generation in both men and women [69]. Studies conducted among older 
adults in NZ in different parts of the country showed that 83% people in the age 
group of above 65 years consumed alcohol and in 9.9 % this was at a hazardous 
level. The study also predicted a prevalence rate of 24.8% of lifetime alcohol 
dependence for 35 out of 141 participants in a community in Christchurch. The study 
also involved an evaluation of GPs (General Practitioner) regarding alcohol use and 
misuse. This study showed that either there is no full awareness amongst GPs about 
the hazardous use of alcohol in the community or the consumption had not reached 
the anticipated levels [69]. Several other literatures have also suggested that alcohol 
use [70] and misuse is not recorded or missed by GPs amongst elderly people [71].  
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Studies have also been conducted on university students in NZ to assess the level of 
binge and alcohol drinking in this population [72]. Many university students are heavy 
drinkers. This may be in part because the legal age enabling purchase of alcohol is 
18 years, and so students have easy access. There was no significant difference 
amongst drinking levels in men and women. It was also noted that participants who 
were hazardous drinkers had experience of unsafe and unwanted sex as compared 
to moderate drinkers [72]. A survey conducted in NZ included 217 participants who 
were all workers in alcohol and drugs treatment service companies. The survey 
results suggest that men are the main clients for these services as compared to 
women and the average age of referral was 31 years.  Most subjects were 
Caucasians, with a high prevalence of drug abuse [73].  
 
Research has also been conducted in NZ to evaluate why there has been a sudden 
increase in consumption of alcohol by adolescents and university students and how 
the media might have played an important role [74]. Broadcasting of beer 
advertisements has increased in the past few years and consumption of beer was 
seen to be higher than wine and spirits. Age factor played an important role in this 
survey. It was noted that males who remembered the alcohol advertisement at the 
age of 15 had consumed 3 times more alcohol at 18 years of age than those who 
could not remember the advertisements at 15 years of age [74]. 
 
4.5 Limitations: 
There were certain significant limitations for our study as follows: 
1. The important covariates used for the analysis in the study were age at 
admission, BMI, alcohol content/day, smoking status, pack years of 
cigarettes, comorbidities, fracture history of bone, age at menarche, physical 
activity status, dietary calcium, any vitamin D supplements or steroids intake. 
We could not investigate the effect of all these covariates together on HUS 
outcomes because often data for all the covariates was not available. This 
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prohibited us from evaluating the effect of all of them together. We performed 
multiple regression to check effect of age at admission, alcohol content/day, 
fracture history and age at menarche on 34 out of 36 participant altogether, 
and found no significant effect of these covariates together on heel ultrasound 
outcomes (Avg BUA, Avg SOS, Avg T score, Avg Z  score and Avg SI). 
 
2. Due to limitations of funds, we performed bone markers on 10 premenopausal 
women only who were admitted at the alcohol unit. We could not collect blood 
samples for the women who participated as controls in the study.  
Furthermore, slow recruitment to the study meant that we were unable to 
reach even this target; future work in larger numbers and incorporating a 
control group is now planned. 
 
 
3. After the time required to obtain ethical approval, there was only a 5 month 
time period for data collection. Hence we were able to obtain data only for 20 
women who were admitted to the unit and fitted the inclusion criteria in the 
period of Jul 2012-Nov 2012. 
 
4.6 Future work: 
We plan to recruit more female participants to this study so that more significant 
results can be obtained. Future work include our aim to obtain extra funding which 
will allow recruitment of more participants for the bone markers sub-study, and to 
incorporate a control group.  
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A2: Ethical Approval for protocol amendment 
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A3: Patient information sheet 
 
 
 
Patient Information Sheet 
 
Study Protocol Title:  Alcohol and bone health: a case control study 
Principal Investigator: 
 
Professor Elaine Dennison, Professor of Clinical Research, Victoria University, 
Wellington 6140 tel: 04 463 5233 
 
 
You are invited to participate in the clinical research study named above. In order to 
determine whether or not to be part of this research study you should understand 
enough about its potential benefits and risks to make an informed judgement.  The 
purpose of this information sheet is to give you that information.  You can keep this 
to take away and read and consider before making up your mind.  Your participation 
is entirely voluntary (your choice).  You do not have to take part in this study, and if 
you choose not to take part you will receive the usual treatment/care.  If you do 
agree to take part you are free to withdraw from the study at any time, without having 
to give a reason and this will in no way affect your future health care.  Participation in 
this study will be stopped if the study doctor feels it is not in your best interest to 
continue. 
 
 
85 
 
 
 
What is the standard treatment? 
This study will assess your bone health, by performing a heel ultrasound test. 
What are the aims of the study?  
 
1. To compare the bone health among healthy women (controls) with women 
admitted to alcohol dependence unit at Kenepuru Hospital using a heel 
ultrasound machine. 
Description of Study 
This is a non-randomised study, which means that everyone will get the same 
treatment. This study will analyse the results from up to 150 patients from one study 
site in New Zealand.  It will take approximately 1 year to accumulate this number of 
patients.   
 
If you agree, after obtaining written consent, you will be invited to complete a 
questionnaire detailing : age, personal and family history of fracture, cigarette 
smoking (pack years), alcohol history (duration and level of drinking; type of alcohol 
consumed), physical activity, dietary calcium intake (food frequency questionnaire), 
past medical history (to elicit information on possible other secondary causes of 
osteoporosis e.g. insulin dependent diabetes, hyperthyroidism), drug history and 
reproductive history. You do not have to answer all the questions, and you may stop 
the interview at any time. Height and weight shall be recorded. Finally, we would like 
to measure the strength and thickness of your bones using a heel ultrasound 
machine. 
 
86 
 
 
 
Are there any risks involved and will I experience any discomfort? 
This clinical research may involve unforeseen risks for you.  The heel ultrasound test 
does not involve any exposure to radiation. 
 
Are there any benefits? 
Through participating in this study, we will learn more about your risk of breaking a 
bone in the future. We can use this information to help you and the doctors looking 
after you make sure that your bones are kept as healthy as possible. The information 
obtained will also help us advise future patients. 
 
Are there alternatives to entering this study? 
Participation in the study is completely voluntary and your usual care will not be 
affected if you decide not to take part. 
 
Will I be made aware of new information regarding the treatment of my 
condition? 
We will feedback your results and some general guidance about your bone health 
 
Confidentiality  
Your name or any other personally identifying information will not be used in reports 
or publications resulting from the study.  Authorised study representatives of the 
research group at Victoria University who coordinate the study, may have limited 
access to medical records.  Study records will be kept in a locked room. 
 
Statement of approval 
‘This study has received ethical approval from the Northern Y Regional Ethics 
Committee’. 
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Further Information or Any Problems 
If you require further information or if you have any problems concerning this project 
(for example, any side effects or injury), you can contact one of the researchers or 
the study coordinator. Contact numbers are:  
Professor Elaine Dennison 
 
Telephone: 04 4635233 
Rights 
If you have any queries or concerns regarding your rights as a participant in this 
study you may wish to contact a Health and Disability Advocate, telephone 
 Northland to Franklin 
 
 0800 555 050 
 Mid and lower North Island 
 0800 42 36 38 (4 ADNET) 
 South Island except Christchurch 
0800 377 766 
 Christchurch 
 03 377 7501 
 
If you have any concerns or complaints about the conduct of a research study can 
contact the Chairperson of the Wellington Ethics Committee on (04) 385 5999 ext 
5185. 
If you would like advice or support from the Maori Health Unit please contact: Jackie 
Davis, Wellington Hospital, on (04) 385 5999 ext 4074. 
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Compensation 
Include for form A studies 
In the unlikely event of a physical injury as a result of your participation in this study, 
you may be covered by ACC under the Injury Prevention, Rehabilitation and 
Compensation Act.  ACC cover is not automatic and your case will need to be 
assessed by ACC according to the provisions of the 2002 Injury Prevention 
Rehabilitation and Compensation Act.  If your claim is accepted by ACC, you still 
might not get any compensation.  This depends on a number of factors such as 
whether you are an earner or non-earner.  ACC usually provides only partial 
reimbursement of costs and expenses and there may be no lump sum compensation 
payable.  There is no cover for mental injury unless it is a result of physical injury.  If 
you have ACC cover, generally this will affect your right to sue the investigators. 
 
 
 
 
 
 
 
 
 
 
 
 
 
89 
 
 
 
A4: Patient Consent form 
 
 
 Patient Consent Form 
 
 
Study Protocol Title: 
 
Alcohol and bone 
 
English 
 
I wish to have an interpreter. Yes No 
Maori 
 
E hiahia ana ahau ki tetahi kaiwhakamaori/kaiwhaka 
pakeha korero. 
Ae Kao 
Samoan 
 
Ou te mana’o ia i ai se fa’amatala upu. Ioe Leai 
Tongan 
 
Oku ou fiema’u ha fakatonulea. Io Ikai 
Cook 
Island 
Ka inangaro au i  tetai tangata uri reo. Ae Kare 
Niuean 
 
Fia manako au ke fakaaoga e taha tagata 
fakahokohoko kupu. 
E Nakai 
 
 
Other languages to be added following consultation 
with relevant communities. 
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I have read and I understand the information sheet dated 18/05/12 for volunteers 
taking part in this study.  I have had the opportunity to discuss this study and I am 
satisfied with the answers I have been given.   
 
I understand that taking part in this study is voluntary (my choice) and that I may 
withdraw from the study at any time and this will in no way affect my continuing 
health care.  
I understand that my participation in this study is confidential and that no material 
which could identify me will be used in any reports on this study.   
I understand that the treatment, or investigation, will be stopped if it should appear 
harmful to me.   
I understand the compensation provisions for this study. 
I have had time to consider whether to take part.   
I know whom to contact if I have any side effects from the study.   
I know whom to contact if I have any questions about the medication or the study.  
I consent to my GP being informed of my participation in this study.                                   
YES/NO 
I …………………………………………………………….hereby consent to take part in 
this study. 
………………………………………… 
 
……………………… 
Patient signature 
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Date 
………………………………………… 
 
……………………… 
Witness signature 
 
 
Date 
To be completed by Doctor (Investigator) 
 
I have discussed with 
……………...…………………………………………………(patient’s name) 
The aims of, procedures and risks involved in this study. 
 
………………………………………… 
 
……………………… 
Doctor’s signature 
 
 
 
 
Date 
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A5: Bone Alcohol Questionnaire for data collection 
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A6: Standard calculation used for dietary calcium content/week 
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106 
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A7: Link for calculating pack years of cigarettes 
 
http://smokingpackyears.com/ 
 
 
A8: Link for calculating alcohol contents/day 
 
http://www.drinkaware.co.uk/tips-and-tools/drink-diary/ 
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